Novel Hexanoic acid derivatives

Abstract

Compounds of the formula 1

Description

BACKGROUND OF THE INVENTION

[0002] The present invention relates to novel hexanoic acid derivatives, methods of use and pharmaceutical compositions containing them.

[0003] The compounds of the invention are potent and selective inhibitors of MIP-1α binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). The CCR1 receptor is also sometimes referred to as the CC-CKR1 receptor. These compounds also inhibit MIP-1α (and the related chemokine shown to interact with CCR1 (e.g., RANTES and MCP-3)) induced chemotaxis of THP-1 cells and human leukocytes and are potentially useful for the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection (chronic and acute), organ rejection (chronic and acute), atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis).

[0004] MIP-1 and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages, J.Biol. Chem., 270 (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells. Elevated levels of chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and rejecting tissue transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran , et al., J. Immunol., 1806-1812 (1996), and Kuna et al., J. Allergy Clin. Immunol. 321 (1994)). Antibodies which interfere with the chemokine/receptor interaction by neutralizing MIP1α or gene disruption have provided direct evidence for the role of MIP-1α and RANTES in disease by limiting the recruitment of monocytes and CD8+ lymphocytes (Smith et al., J. Immunol, 153, 4704 (1994) and Cook et al., Science, 269, 1583 (1995)). Together this data demonstrates that CCR1 antagonists would be an effective at treatment of several immune

[0005] U.S. Pat. No. 4,923,864, issued May 8, 1990, refers to certain heterocyclic hexanamides that are useful for treating hypertension.

[0006] PCT publication WO 89/01488, published Feb. 23, 1989, refers to renin inhibiting peptides which possess nonpeptide linkages.

[0007] PCT publication WO 93/025057, published Feb. 4, 1993, refers to dipeptide analogs which are claimed to inhibit retroviral proteases.

[0008] PCT publication WO 93/17003, published Sep. 2, 1993, refers to other dipeptide analogs which are claimed to inhibit retroviral proteases.

[0009] PCT publication WO 92/17490, published Oct. 15, 1992, refers to peptides containing at least one O-phosphate monoester or diester. The compounds are claimed to possess activity for inhibiting retroviruses.

[0010] European Patent Publication 708,085, published Apr. 24, 1996, refers to antiviral ethers of aspartate protease inhibitors.

SUMMARY OF THE INVENTION

[0011] The present invention relates to compounds of the formula 2

[0012] wherein R1 is (C2-C9)heteroaryl optionally substituted with one or more substituents (preferably one to three substituents) independently selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C8)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6)alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C8)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)—(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkyl HN—SO2—(C1-C6)alkyl, [(C1-C6)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3—, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl;

[0013] R2 is phenyl-(CH2)m—, naphthyl-(CH2)m—, (C3-C10)cycloalkyl-(CH2)m—, (C1-C6)alkyl or (C2-C9)heteroaryl-(CH2)m—, wherein m is an interger from zero to four, wherein each of said phenyl, naphthyl, (C3-C10)cycloalkyl or (C2-C9)heteroaryl moieties of said phenyl-(CH2)m—, naphthyl-(CH2)m—, (C3-C10)cycloalkyl-(CH2)m— or (C2-C9)heteroaryl-(CH2)m— groups may optionally be substituted with one or more substituents (preferably one to three substituents) independently selected from hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6)alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)—(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkylHN—SO2—(C1-C6)alkyl, [(C1-C8)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3-phenyl, phenoxy, benzyloxy, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl;

[0014] R3 is hydrogen, (C1-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n—, (C2-C9)heterocycloalkyl-(CH2)n—, (C2-C9)heteroaryl-(CH2)n— or aryl-(CH2)n—; wherein n is an interger from zero to six;

[0015] wherein said R3 (C1-C10)alkyl group may optionally be substituted with one or more substituents, (preferably from one to three substituents) independently selected from hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6)alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-N H-(C═O)—, [(C1-C6)al kyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)—(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkylHN—SO2—(C1-C6)alkyl, [(C1-C6)alkY]2 N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3—, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; and wherein any of the carbon-carbon single bonds of said (C1-C10)alkyl may optionally be replaced by a carbon-carbon double bond;

[0016] wherein the (C3-C10)cycloalkyl moiety of said R3 (C3-C10)cycloalkyl-(CH2)n— group may optionally be substituted by one to three substitutents independently selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6)alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)—(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkyl HN—SO2—(C1-C6)alkyl, [(C1-C6)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3—, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl;

[0017] wherein the (C2-C9)heterocycloalkyl moiety of said R3 (C2-C9)heterocycloalkyl-(CH2)n— group may contain from one to three heteroatoms independently selected from nitrogen, sulfur, oxygen, >S(═O), >SO2 or >NR6, wherein said (C2-C9)heterocycloalkyl moiety of said (C2-C9)heterocycloalkyl-(CH2)n— group may optionally be substituted on any of the ring carbon atoms capable of forming an additional bond (preferably one to three substitutents per ring) with a substituent independently selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6)alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)—(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkylHN—SO2—(C1-C6)alkyl, [(C1-C6)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3—, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl;

[0018] wherein the (C2-C9)heteroaryl moiety of said R3 (C2-C9)heteroaryl-(CH2)n— group may contain from one to three heteroatoms independently selected from nitrogen, sulfur or oxygen, wherein said (C2-C9)heteroaryl moiety of said (C2-C9)heteroaryl-(CH2)r— group may optionally be substituted on any of the ring carbon atoms capable of forming an additional bond (preferably one to three substitutents per ring) with a substituent selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6)alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)—(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkylHN—SO2—(C1-C6)alkyl, [(C1-C6)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3-phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; and

[0019] wherein said aryl moiety of said R3 aryl-(CH2)n— group is optionally substituted phenyl or naphthyl, wherein said phenyl and naphthyl may optionally be substituted with from one to three substituents independently selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6)alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)-(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkyl HN—SO2-(C1-C6)alkyl, [(C1-C6)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3—, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl;

[0020] or R3 and the carbon to which it is attached form a five to seven membered carbocyclic ring, wherein any of the carbon atoms of said five membered carbocyclic ring may optionally be substituted with a substituent selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6)alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)-(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkylHN—SO2—(C1-C6)alkyl, [(C1-C6)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3—, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; wherein one of the carbon-carbon bonds of said five to seven membered carbocyclic ring may optionally be fused to an optionally substituted phenyl ring, wherein said substitutents may be independently selected from hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6)alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-N H-(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)-(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkylHN—SO2—(C1-C6)alkyl, [(C1-C6)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3—, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl;

[0021] R4 is hydrogen, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C═O)—, (C3-C10)cycloalkyl-(CH2)p—, (C2-C9)heterocycloalkyl-(CH2)p—, (C2-C9)heteroaryl-(CH2)p—, phenyl-(CH2)p—, or naphthyl-(CH2)p—, wherein p is an integer from zero to four; wherein said (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl, phenyl and naphthyl groups of said (C2-C9)heterocycloalkyl-(CH2)p—, (C2-C9)heteroaryl-(CH2)p—, phenyl-(CH2)p—, or naphthyl-(CH2)p— may be optionally substituted on any of the ring atoms capable of supporting an additional bond (preferably zero to two substituents per ring) with a substituent selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C8)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6) alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2 amino, amino(C1-C6)alkyl, (C1-C6)alkylamino (C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)—(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkylHN—SO2—(C1-C6)alkyl, [(C1-C6)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl;

[0022] or R4 and R5 together with the nitrogen atom to which they are attached form a (C2-C9)heterocycloalkyl group wherein any of the ring atoms of said (C2-C9)heterocycloalkyl group may optionally be substituted, preferably from zero to two substituents, with a substituent selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO—(C═O)—, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H(O═C)—, H(O═C)—(C1-C6)alkyl, (C1-C6) alkyl(O═C)—, (C1-C6)alkyl(O═C)—(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2 amino, amino(C1-C6)alkyl, (C1-C6)alkylamino (C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)—(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S—, (C1-C6)alkyl-(S═O)—, (C1-C6)alkyl-SO2—, (C1-C6)alkyl-SO2—NH—, H2N—SO2—, H2N—SO2—(C1-C6)alkyl, (C1-C6)alkylHN—SO2—(C1-C6)alkyl, [(C1-C6)alkyl]2N—SO2—(C1-C6)alkyl, CF3SO3—, (C1-C6)alkyl-SO3—, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl;

[0023] R5 is hydrogen, (C1-C6)alkyl or amino;

[0024] R6 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy-(CH2)g—, (C1-C6)alkoxy(C═O)—(CH2)g—, (C1-C6)alkyl-(SO2)—(CH2)9—, (C6-C10)aryloxy-(CH2)9—, (C6-C10)aryloxy(C═O)—(CH2)9—, or (C1-C10)aryl-(SO2)—(CH2)9—, wherein g is an integer from zero to four;

[0025] with the proviso that when one of R4 or R5 is hydrogen, and the other of R4 or R5 is (C1-C6)alkyl; R2 is (C3-C10)cycloalkyl or isopropyl and R3 is (C3-C5)alkyl, phenyl, methylvinyl, dimethylvinyl, halovinyl, hydroxy(C1-C3)alkyl or amino(C1-C4)alkyl then R1 must be other than indol-5-yl, 6-azaindol-2-yl, 2,3-dichloro-pyrrol-5-yl, 4-hydroxyquinolin-3-yl, 2-hydroxyquinoxalin-3-yl, 6-azaindolin-3-yl, or optionally substituted indol-2 or 3-yl;

[0026] and the pharmaceutically acceptable salts of such compounds.

[0027] The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)]salts.

[0028] The invention also relates to base addition salts of formula I. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.

[0029] The compounds of this invention may contain olefin-like double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof.

[0030] Unless otherwise indicated, the alkyl and alkenyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e.g., alkoxy), may be linear or branched, and they may also be cyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl) or be linear or branched and contain cyclic moieties. Unless otherwise indicated, halogen includes fluorine, chlorine, bromine, and iodine.

[0031] (C3-C10)Cycloalkyl when used herein refers to cycloalkyl groups containing zero to two levels of unsaturation such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, 1,3-cyclohexadiene, cycloheptyl, cycloheptenyl, bicyclo[3.2.1 ]octane, norbornanyl etc.

[0032] (C2-C9)Heterocycloalkyl when used herein refers to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl, chromanyl, etc. One of ordinary skill in the art will understand that the connection of said (C2-C9)heterocycloalkyl rings is through a carbon or a sp3 hybridized nitrogen heteroatom.

[0033] (C2-C9)Heteroaryl when used herein refers to furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5,6,7,8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, -benzoxazinyl; etc. One of ordinary skill in the art will understand that the connection of said (C2-C9)heterocycloalkyl rings is through a carbon atom or a s hybridized nitrogen heteroatom.

[0034] Aryl when used herein refers to phenyl or naphthyl.

[0035] The compounds of this invention include all conformational isomers (e.g., cis and trans isomers) and all optical isomers of compounds of the formula I (e.g., enantiomers and diastereomers), as well as racemic, diastereomeric and other mixtures of such isomers.

[0036] Preferred compounds of the of formula I include those with the stereochemistry depicted in formula 3

[0037] Preferred compounds of the formula I include those wherein R1 is optionally substituted pyrazolo[3,4-b]pyridinyl, cinnolinyl, pyridinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzothiazolyl, indolyl, pyrazinyl, benzoimidazolyl, benzofuranyl, benzo[b]thiophenyl, naphthalenyl, quinoxalinyl, isoquinolinyl, 5,6,7,8-tetrahydro-quinolin-3-yl or quinolinyl, more preferably pyrazolo[3,4-b]pyridin-5-yl, cinnolin-4-yl, pyridin-2-yl, 6,7-dihydro-5H-[1]pyrindin-3-yl, benzothiazol-2-yl, indol-2-yl, pyrazin-2-yl, benzoimidazol-2-yl, benzofuran-2-yl, benzo[b]thiophen-2-yl, naphthalen-2-yl, quinoxalin-2-yl, quinoxalin-6-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, 5,6,7,8-tetrahydro-quinolin-3-yl, quinolin-2-yl, quinolin-3-yl, quinolin-4-yl or quinolin-6-yl, most preferably quinoxalin-6-yl, quinolin-2-yl, quinolin-3-yl, quinoxalin-2-yl, quinolin-4-yl or quinolin-6-yl.

[0038] Other preferred compounds of formula I include those wherein R2 is optionally substituted phenyl, benzyl, naphthyl, cyclohexyl, thienyl, thiazolyl, pyridyl, oxazolyl, furanyl, or thiophenyl; wherein said substituents are independently selected from hydrogen, halo, (C1-C6)alkyl, trifluoromethyl, trifluoromethoxy, hydroxy, —C(═O)—OH, (C1-C6)alkoxy, (C1-C6)alkoxy(C═O)—, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, (C1-C6)alkyl-O—(C═O)—, HO—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-O—(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-(C═O)—O—, (C1-C6)alkyl-(C═O)—O—(C1-C6)alkyl, H2N—(C═O)—, (C1-C6)alkyl-NH—(C═O)—, [(C1-C6)alkyl]2N—(C═O)—, H2N(C═O)—(C1-C6)alkyl, (C1-C6)alkyl-HN(C═O)—(C1-C6)alkyl, [(C1-C6)alkyl]2N—(C═O)—(C1-C6)alkyl, H(O═C)—NH—, (C1-C6)alkyl(C═O)—NH, (C1-C6)alkyl(C═O)—[NH](C1-C6)alkyl, (C1-C6)alkyl(C═O)—[N(C1-C6)alkyl](C1-C6)alkyl, phenoxy, and benzyloxy.

[0039] Other preferred compounds of formula I include those wherein R3 is optionally substituted (C1-C10)alkyl, benzyl, pyranyl or (C3-C10)cycloalkyl-(CH2)n—, wherein any of the carbon-carbon single bonds of said (C1-C10)alkyl may be optionally replaced by a carbon-carbon double bond; more preferably optionally substituted n-butyl, isobutyl, n-pentyl, 3-methyl-butyl, 2-methyl-pentyl, allyl, cyclopentyl, cyclohexyl or cycloheptyl, more preferably wherein the substituent is fluoro, (C1-C6)alkyl or hydroxy.

[0040] Examples of specific preferred compounds of the formula I are the following:

[0041] 7,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0042] 8-fluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0043] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-7-fluoro-1(S)-(3-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide;

[0044] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(2-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide;

[0045] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-4-(2,6-dimethyl-tetrahydro-pyran-4-yl)-2(S)-hydroxy-butyl]-amide;

[0046] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)]-amide;

[0047] quinoxaline-2-carboxylic acid [1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)]-amide;

[0048] quinoxaline-2-carboxylic acid [1(S)-cyclohexylmethyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)]-amide;

[0049] quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0050] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-(4,4-difluoro-1-hydroxy-cyclohexyl)-2(S)-(hydroxy-4-hydroxycarbamoyl-butyl )]-amide;

[0051] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-4(S)-(4,4-difluoro-cyclohexyl)-2(S)-hydroxy-butyl]-amide;

[0052] quinoline-3-carboxylic acid (1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-butyl)-amide;

[0053] quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-1(S)-thiophen-2-ylmethyl-octyl)-amide;

[0054] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-7-chloro-2(S)-hydroxy-oct-6-enyl)]-amide;

[0055] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl-pentyl)]-amide;

[0056] N-(1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-5,6-dichloro-nicotinamide;

[0057] quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-1(S)-thiazol-4-ylmethyl-octyl)-amide;

[0058] benzothiazole-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)]-amide; and

[0059] benzofuran-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)]-amide.

[0060] Examples of other compounds of the formula I are the following:

[0061] quinoxaline-2-carboxylic acid (4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-1-thiazol-4-ylmethyl-octyl)-amide;

[0062] quinoxaline-2-carboxylic acid (7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-1-thiazol-4-ylmethyl-octyl)-amide;

[0063] quinoxaline-2-carboxylic acid [4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-1-thiazol-4-ylmethyl-butyl]-amide;

[0064] quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-thiazol-4-ylmethyl-butyl]-amide;

[0065] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-thiazol-4-ylmethyl-butyl]-amide;

[0066] quinoxaline-2-carboxylic acid [4-(4,4-difluoro-cyclohexyl)-2-hydroxy-4-hydroxycarbamoyl-1-thiazol-4-ylmethyl-butyl]-amide;

[0067] quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3,5-difluoro-benzyl)-7-fluoro-2-hydroxy-7-methyl-octyl]-amide;

[0068] quinoxaline-2-carboxylic acid [1-(3,5-difluoro-benzyl)-7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-octyl]-amide;

[0069] quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3,5-difluoro-benzyl)-2-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0070] quinoxaline-2-carboxylic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0071] quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3,5-difluoro-benzyl)-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-butyl]-amide;

[0072] quinoxaline-2-carboxylic acid [1-(3,5-difluoro-benzyl)-4-(4,4-difluoro-cyclohexyl )-2-hydroxy-4-hydroxycarbamoyl-butyl]-amide;

[0073] quinoxaline-2-carboxylic acid (4-carbamoyl-2-hydroxy-7-methyl-1-pyridin-2-ylmethyl-octyl)-amide;

[0074] quinoxaline-2-carboxylic acid (7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-1-pyridin-2-ylmethyl-octyl)-amide;

[0075] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(2,6-dimethyl-tetrahydro-pyran-4-yl)-2-hydroxy-1-pyridin-2-ylmethyl-butyl]-amide;

[0076] quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-pyridin-2-ylmethyl-butyl]-amide;

[0077] quinoxaline-2-carboxylic acid (4-carbamoyl-4-cyclohexyl-2-hydroxy-1-pyridin-2-ylmethyl-butyl)-amide;

[0078] quinoxaline-2-carboxylic acid [4-(4,4-difluoro-cyclohexyl)-2-hydroxy-4-hydroxycarbamoyl-1-pyridin-2-ylmethyl-butyl]-amide;

[0079] quinoxaline-2-carboxylic acid (4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-1-pyridin-3-ylmethyl-octyl)-amide;

[0080] quinoxaline-2-carboxylic acid (2-hydroxy-4-hydroxycarbamoyl-7-methyl-1-pyridin-3-ylmethyl-octyl)-amide;

[0081] quinoxaline-2-carboxylic acid [4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-1-pyridin-3-ylmethyl-butyl]-amide;

[0082] quinoxaline-2-carboxylic acid [4-(2,6-dimethyl-tetrahydro-pyran-4-yl)-2-hydroxy-4-hydroxycarbamoyl-1-pyridin-3-ylmethyl-butyl]-amide;

[0083] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-pyridin-3-ylmethyl-butyl]-amide;

[0084] quinoxaline-2-carboxylic acid (4-cyclohexyl-2-hydroxy-4-hydroxycarbamoyl-1-pyridin-3-ylmethyl-butyl)-amide;

[0085] quinoxaline-2-carboxylic acid [4-carbamoyl-7-fluoro-1-(4-fluoro-benzyl)-2-hydroxy-7-methyl-octyl]-amide;

[0086] quinoxaline-2-carboxylic acid [7-fluoro-1-(4-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-7-methyl-octyl]-amide;

[0087] quinoxaline-2-carboxylic acid [4-carbamoyl-1-(4-fluoro-benzyl)-2-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0088] quinoxaline-2-carboxylic acid [1-(4-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0089] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-1-(4-fluoro-benzyl)-2-hydroxy-butyl]-amide;

[0090] quinoxaline-2-carboxylic acid [4-(4,4-difluoro-cyclohexyl)-1-(4-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-butyl]-amide;

[0091] quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluoro-benzyl)-2-hydroxy-4-(1-hydroxy-cyclohexyl)-butyl]-amide;

[0092] quinoxaline-2-carboxylic acid [7-fluoro-1-(3-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-7-methyl-octyl]-amide;

[0093] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(2,6-dimethyl-tetrahydro-pyran-4-yl)-1-(3-fluoro-benzyl)-2-hydroxy-butyl]-amide;

[0094] quinoxaline-2-carboxylic acid [1-(3-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0095] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-1-(3-fluoro-benzyl)-2-hydroxy-butyl]-amide;

[0096] quinoxaline-2-carboxylic acid [4-cyclohexyl-1-(3-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-butyl]-amide;

[0097] quinoxaline-2-carboxylic acid [4-carbamoyl-1-(2-fluoro-benzyl)-2-hydroxy-4-(1-hydroxy-cyclohexyl)-butyl]-amide;

[0098] quinoxaline-2-carboxylic acid [7-fluoro-1-(2-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-7-methyl-octyl]-amide;

[0099] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(2,6-dimethyl-tetrahydro-pyran-4-yl)-1-(2-fluoro-benzyl)-2-hydroxy-butyl]-amide;

[0100] quinoxaline-2-carboxylic acid [1-(2-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0101] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-1-(2-fluoro-benzyl)-2-hydroxy-butyl]-amide;

[0102] quinoxaline-2-carboxylic acid [4-cyclohexyl-1-(2-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-butyl]-amide;

[0103] quinoxaline-2-carboxylic acid (4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-1-thiophen-2-ylmethyl-octyl)-amide;

[0104] quinoxaline-2-carboxylic acid (7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-1-thiophen-2-ylmethyl-octyl)-amide;

[0105] quinoxaline-2-carboxylic acid [4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-1-thiophen-2-ylmethyl-butyl]-amide;

[0106] quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-thiophen-2-ylmethyl-butyl]-amide;

[0107] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-thiophen-2-ylmethyl-butyl]-amide;

[0108] quinoxaline-2-carboxylic acid [4-(4,4-difluoro-cyclohexyl)-2-hydroxy-4-hydroxycarbamoyl-1-thiophen-2-ylmethyl-butyl]-amide;

[0109] quinoxaline-2-carboxylic acid [4-carbamoyl-2-hydroxy-7-methyl-1-(3-trifluoromethyl-benzyl)-octyl]-amide;

[0110] quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-1-(3-trifluoromethyl-benzyl)-octyl]-amide;

[0111] quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(4-hydroxy-2,6-dimethyl-tetrahydro-pyran-4-yl)-1-(3-trifluoromethyl-benzyl)-butyl]-amide;

[0112] quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-(3-trifluoromethyl-benzyl)-butyl]-amide;

[0113] quinoxaline-2-carboxylic acid {4-carbamoyl-4-cyclohexyl)-2-hydroxy-1-(3-trifluoromethyl-benzyl)-butyl}-amide;

[0114] quinoxaline-2-carboxylic acid {4-hydroxycarbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-(3-trifluoromethyl-benzyl)-butyl}-amide;

[0115] quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-carbamoyl-7-methyl-1-(3-trifluoromethoxy-benzyl)-octyl]-amide;

[0116] quinoxaline-2-carboxylic acid [4-hydroxycarbamoyl-2-hydroxy-7-methyl-1-(3-trifluoromethoxy-benzyl)-octyl]-amide;

[0117] quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-(3-trifluoromethoxy-benzyl)-butyl]-amide;

[0118] quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(4-hydroxy-2,6-dimethyl-tetrahydro-pyran-4-yl)-1-(3-trifluoromethoxy-benzyl)-butyl]-amide;

[0119] quinoxaline-2-carboxylic acid {4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-(3-trifluoromethoxy-benzyl)-butyl}-amide;

[0120] quinoxaline-2-carboxylic acid {4-hydroxycarbamoyl-4-cyclohexyl)-2-hydroxy-1-(3-trifluoromethoxy-benzyl)-butyl}-amide;

[0121] quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-carbamoyl-7-methyl-1-(4-trifluoromethoxy-benzyl)-octyl]-amide;

[0122] quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-1-(4-trifluoromethoxy-benzyl)-octyl]-amide;

[0123] quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-(4-trifluoromethoxy-benzyl)-butyl]-amide;

[0124] quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-(4-trifluoromethoxy-benzyl)-butyl]-amide;

[0125] quinoxaline-2-carboxylic acid {4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-(4-trifluoromethoxy-benzyl)-butyl}-amide;

[0126] quinoxaline-2-carboxylic acid {4-hydroxycarbamoyl-4-(4,4-difluoro-cyclohexyl )-2-hydroxy-1-(4-trifluoromethoxy-benzyl)-butyl}-amide;

[0127] quinoxaline-2-carboxylic acid [4-carbamoyl-2-hydroxy-7-methyl-1-(2-trifluoromethyl-benzyl)-octyl]-amide;

[0128] quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-1-(2-trifluoromethoxy-benzyl)-octyl]-amide;

[0129] quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(4-hydroxy-2,6-dimethyl-tetrahydro-pyran-4-yl)-1-(2-trifluoromethoxy-benzyl)-butyl]-amide;

[0130] quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-(2-trifluoromethoxy-benzyl)-butyl]-amide;

[0131] quinoxaline-2-carboxylic acid {4-carbamoyl-4-cyclohexyl)-2-hydroxy-1-(2-trifluoromethoxy-benzyl)-butyl}-amide;

[0132] quinoxaline-2-carboxylic acid {4-hydroxycarbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-(2-trifluoromethoxy-benzyl)-butyl}-amide;

[0133] quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-carbamoyl-7-methyl-1-[3-(1-hydroxy-1-methyl-ethyl)-benzyl]-octyl]-amide;

[0134] quinoxaline-2-carboxylic acid [4-hydroxycarbamoyl-2-hydroxy-7-methyl -1-[3-(1-hydroxy-1-methyl-ethyl)-benzyl]-octyl]-amide;

[0135] quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-[3-(1-hydroxy-1-methyl-ethyl)-benzyl]-butyl]-amide;

[0136] quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(4-hydroxy-2,6-dimethyl-tetrahyd ro-pyran-4-yl)-1-3-(1-hydroxy-1-methyl-ethyl)-benzyl)-butyl]-amide;

[0137] quinoxaline-2-carboxylic acid {4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-[3-(1-hydroxy-1-methyl-ethyl)-benzyl]-butyl}-amide;

[0138] quinoxaline-2-carboxylic acid {4-hydroxycarbamoyl-4-(cyclohexyl)-2-hydroxy-1-[3-(1-hydroxy-1-methyl-ethyl)-benzyl]-butyl}-amide;

[0139] quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-carbamoyl-7-methyl-1-thiophen-3-ylmethyl-butyl]-amide;

[0140] quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-1-thiophen-3-ylmethyl-butyl]-amide;

[0141] quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-thiophen-3-ylmethyl-butyl]-amide;

[0142] quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-1-thiophen-3-ylmethyl-butyl]-amide;

[0143] quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-thiophen-3-ylmethyl-butyl]-amide;

[0144] quinoxaline-2-carboxylic acid [4-hydroxycarbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1-thiophen-3-ylmethyl-butyl]-amide;

[0145] [[1,8]naphthyridine-3-carboxylic acid (1-benzyl-4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-octyl)-amide;

[0146] [1,8]naphthyridine-3-carboxylic acid (1-benzyl-7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-octyl)-amide;

[0147] [1,8]naphthyridine-3-carboxylic acid [1-benzyl-4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0148] [1,8]naphthyridine-3-carboxylic acid [1-benzyl-2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0149] [1,5] naphthyridine-3-carboxylic acid (1-benzyl-4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-octyl)-amide;

[0150] [1,5]naphthyridine-3-carboxylic acid (1-benzyl-7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-octyl)-amide;

[0151] [1,5]naphthyridine-3-carboxylic acid [1-benzyl-4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0152] [1,5]naphthyridine-3-carboxylic acid [1-benzyl-2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0153] [1,8] naphthyridine-2-carboxylic acid (1-benzyl-4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-octyl)-amide;

[0154] [1,8]naphthyridine-2-carboxylic acid (1-benzyl-7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-octyl)-amide;

[0155] [1,8]naphthyridine-2-carboxylic acid [1-benzyl-4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0156] [1,8]naphthyridine-2-carboxylic acid [1-benzyl-2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0157] [1,6] naphthyridine-2-carboxylic acid (1-benzyl-4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-octyl)-amide;

[0158] [1,6]naphthyridine-2-carboxylic acid (1-benzyl-7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-octyl)-amide;

[0159] [1,6]naphthyridine-2-carboxylic acid [1-benzyl-4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0160] [1,6]naphthyridine-2-carboxylic acid [1-benzyl-2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0161] quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0162] quinoxaline-2-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0163] quinoxaline-2-carboxylic acid (6-chloro-1(S)-cyclohexyl methyl-2(S)-hydroxy-4(S)-methylcarbamoyl-hept-6-enyl)-amide;

[0164] quinoline-3-carboxylic acid (2(S)-hydroxy-1(S)-isobutyl-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0165] quinoxaline-2-carboxylic acid 1(S)-sec-butyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0166] quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-hept-6-enyl)-amide;

[0167] quinoxaline-2-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-hept-6-enyl)-amide;

[0168] N-1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-5-phenyl-nicotinamide;

[0169] quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0170] quinoxaline-2-carboxylic acid 1(S)-cyclohexylmethyl-4(R)-dimethylcarbamoyl-2(S)-hydroxy-6-methyl-hept-6-enyl)-amide;

[0171] quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0172] quinoxaline-2-carboxylic acid 1(S)-cyclohexyl methyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0173] isoquinoline-4(R)-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0174] quinoline-3-carboxylic acid (4(R)-carbamoyl-1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-heptyl)-amide;

[0175] quinoline-3-carboxylic acid (5-cyclohexyl-1(S)-cyclohexylmethyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0176] quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0177] quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(S)-methylcarbamoyl-heptyl)-amide;

[0178] quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-4(R)-methylcarbamoyl-5-phenyl-pentyl)-amide;

[0179] quinoxaline-2-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-4(R)-methylcarbamoyl-5-phenyl-pentyl)-amide;

[0180] quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-butylcarbamoyl-2(S)-hydroxy-6-methyl-heptyl)-amide;

[0181] quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-cyclobutylcarbamoyl-2(S)-hydroxy-6-methyl-heptyl)-amide;

[0182] quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-benzylcarbamoyl-2(S)-hydroxy-6-methyl-heptyl)-amide;

[0183] quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-cyclopropylcarbamoyl-2(S)-hydroxy-6-methyl-heptyl)-amide;

[0184] quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(S)-methylcarbamoyl-heptyl)-amide;

[0185] quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-ethylcarbamoyl-2(S)-hydroxy-6-methyl-heptyl)-amide;

[0186] quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-propylcarbamoyl-heptyl)-amide;

[0187] quinoline-3-carboxylic acid [1-benzyl-2(S)-hydroxy-4(R)-(2(S)-hydroxy-ethylcarbamoyl)-6-methyl-heptyl]-amide;

[0188] cinnoline-4(R)-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0189] isoquinoline-4(R)-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0190] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0191] N-1(S)-Benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-5-bromo-nicotinamide;

[0192] quinoline-3-carboxylic acid 1(R)-cyclohexylmethyl-2(R)-hydroxy-6-methyl-4(S)-methylcarbamoyl-heptyl)-amide;

[0193] quinoxaline-2-carboxylic acid [1-(4-benzyloxy-benzyl)-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0194] quinoline-3-carboxylic acid [1-(4-benzyloxy-benzyl)-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0195] isoquinoline-1-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0196] quinoline-4(R)-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0197] quinoline-6-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0198] quinoline-3-carboxylic acid [2(S)-hydroxy-1-(4-hydroxy-benzyl)-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0199] quinoline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0200] naphthalene-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0201] quinoline-3-carboxylic acid 1(S)-benzyl-5-cyclohex-1-enyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0202] quinoline-3-carboxylic acid [1-benzyl-2(S)-hydroxy-6-methyl-4(R)-(3-methyl-butylcarbamoyl)-heptyl]-amide;

[0203] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(S)-methylcarbamoyl-heptyl)-amide;

[0204] trifluoro-methanesulfonic acid 4-{3(S)-hydroxy-7-methyl-5(R)-methylcarbamoyl-2(S)-[(quinoline-3-carbonyl)-amino]-octyl}-phenyl ester;

[0205] trifluoro-methanesulfonic acid 4-{3(S)-hydroxy-7-methyl-5(R)-methylcarbamoyl-2(S)-[(quinoxaline-2-carbonyl)-amino]-octyl}-phenyl ester;

[0206] quinoline-3-carboxylic acid 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0207] quinoxaline-2-carboxylic acid 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0208] isoquinoline-3-carboxylic acid 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0209] N-1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-5-bromo-nicotinamide;

[0210] quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-prop-2-ynylcarbamoyl-heptyl)-amide;

[0211] quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-4(R)-hydroxycarbamoyl-6-methyl-heptyl)-amide;

[0212] quinoline-3-carboxylic acid 2(S)-hydroxy-1(S)-(4-methoxy-benzyl)-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0213] isoquinoline-3-carboxylic acid (5-cyclohexyl-1(S)-cyclohexylmethyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0214] 5-bromo-N-(5-cyclohexyl-1(S)-cyclohexylmethyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-nicotinamide;

[0215] quinoxaline-2-carboxylic acid [2(S)-hydroxy-1(S)-(4-methoxy-benzyl)-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0216] isoquinoline-4(R)-carboxylic acid (5-cyclohexyl-1(S)-cyclohexylmethyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0217] quinoline-2-carboxylic acid 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0218] isoquinoline-4(R)-carboxylic acid 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0219] quinoxaline-2-carboxylic acid [2(S)-hydroxy-1(S)-(4-hydroxy-benzyl)-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0220] quinoxaline-2-carboxylic acid (5-cyclohexyl-1(S)-cyclohexylmethyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0221] quinoline-3-carboxylic acid [1(S)-(4-chloro-benzyl)-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0222] quinoxaline-2-carboxylic acid [1(S)-(4-chloro-benzyl)-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0223] quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0224] quinoxaline-2-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0225] quinoline-3-carboxylic acid [1(S)-(4-chloro-benzyl)-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl]-amide;

[0226] quinoxaline-2-carboxylic acid [1(S)-(4-chloro-benzyl)-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl]-amide;

[0227] quinoline-2-carboxylic acid [1(S)-(4-chloro-benzyl)-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl]-amide;

[0228] benzofuran-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0229] N-1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-5,6-dichloro-nicotinamide;

[0230] quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0231] N-1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-5-bromo-nicotinamide;

[0232] 5,6,7,8-tetrahydro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0233] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0234] quinoline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0235] isoquinoline-4(R)-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0236] quinoxaline-2-carboxylic acid [1-(3,4-dichloro-benzyl)-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0237] benzo[b]thiophene-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl )-amide;

[0238] 2-methyl-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0239] 6,7-dimethoxy-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0240] 6,7-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0241] 1H-benzoimidazole-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0242] 5-methyl-pyrazine-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0243] quinoline-3-carboxylic acid [1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0244] quinoxaline-2-carboxylic acid [1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0245] 5-chloro-1H-indole-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0246] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0247] 2-methoxy-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcabamoyl-heptyl)-amide;

[0248] 5,6-dichloro-1H-benzoimidazole-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0249] benzothiazole-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0250] 7,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0251] 6 7,8-trifluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0252] 5,8-dimethyl-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0253] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-butylcarbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0254] quinoline-3-carboxylic acid [1(S)-(3,4-dichloro-benzyl)-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0255] 5,6,7,8-tetrahydro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0256] quinoline-3-carboxylic acid 1(S)-benzyl-5-cyclopentyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0257] quinoxaline-2-carboxylic acid 1(S)-benzyl-5-cyclopentyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0258] N-1(S)-benzyl-5-cyclopentyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-5-bromo-nicotinamide;

[0259] 5,6,7,8-tetrahydro-quinoline-3-carboxylic acid 1(S)-benzyl-5-cyclopentyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide;

[0260] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-5-cyclopentyl-2(S)-hydroxy-pentyl)-amide;

[0261] 6,7-dihydro-5H-[1 ]pyrindine-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0262] quinoxaline-2-carboxylic acid [1(S)-(4,4-difluoro-cyclohexylmethyl)-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl]-amide;

[0263] quinoxaline-2-carboxylic acid [1(S)-(4,4-difluoro-cyclohexylmethyl)-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl]-amide;

[0264] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-ethylcarbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0265] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-propylcarbamoyl-octyl)-amide;

[0266] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-cyclopropylcarbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0267] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-cyclobutylcarbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0268] quinoxaline-2-carboxylic acid [1(S)-(4-difluoromethoxy-benzyl)-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl]-amide;

[0269] 4-{3(S)-hydroxy-7-methyl-5(R)-methylcarbamoyl-2(S)-[(quinoxaline-2-carbonyl)-amino]-octyl}-benzoic acid methyl ester;

[0270] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-butyl)-amide;

[0271] 6,7,8-trifluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0272] 6,7,8-trifluoro-quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0273] 6,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0274] 6,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0275] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-butylcarbamoyl-5-cyclopentyl-2(S)-hydroxy-pentyl)-amide;

[0276] 6-methyl-pyridine-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl)-amide;

[0277] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-8-methyl-4(R)-methylcarbamoyl-nonyl)-amide;

[0278] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-8-methyl-nonyl)-amide;

[0279] quinoxaline-2-carboxylic acid 1(S)-biphenyl-4(R)-ylmethyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0280] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl-oct-6-enyl)-amide;

[0281] quinoxaline-2-carboxylic acid (2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-1(S)-naphthalen-2-ylmethyl-heptyl)-amide;

[0282] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7,7-dimethyl-octyl)-amide;

[0283] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7,7-dimethyl-4(R)-methylcarbamoyl-octyl)-amide;

[0284] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl-pentyl)-amide;

[0285] quinoxaline-2-carboxylic acid 1(S)-biphenyl-4(R)-ylmethyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0286] quinoxaline-2-carboxylic acid [1(S)-benzyl-5-(4,4-difluoro-cyclohexyl)-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl]-amide;

[0287] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-5-(4,4-difluoro-cyclohexyl)-2(S)-hydroxy-pentyl]-amide;

[0288] quinoxaline-2-carboxylic acid [1(S)-(3-fluoro-benzyl)-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl]-amide;

[0289] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(3(S)-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide;

[0290] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-oct-6-enyl)-amide;

[0291] 6,7,8-trifluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-nonyl)-amide;

[0292] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl-nonyl)-amide;

[0293] quinoxaline-2-carboxylic acid 1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0294] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0295] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-nonyl)-amide;

[0296] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-dimethylcarbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0297] 7,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-4(R)-methylcarbamoyl-5-phenyl-pentyl)-amide;

[0298] 7,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0299] 8-fluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide;

[0300] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-4(R)-methylcarbamoyl-non-6-enyl)-amide;

[0301] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-non-6-enyl)-amide;

[0302] 7,8 difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl-octyl )-amide;

[0303] 8-fluoro-quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide;

[0304] 4(S)hydroxy-2(R)-(3-methyl-butyl)-6-phenyl-5(S)-[(quinoxaline-2(R)-carbonyl)-amino]-hexanoic acid;

[0305] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-nonyl)-amide;

[0306] 2-{2(S)-hydroxy-4-phenyl-3(S)-[(quinoxaline-2-carbonyl)-amino]-butyl}-N1, N4-dimethyl-succinamide;

[0307] quinoxaline-2-carboxylic acid 1(S)-benzyl-4-ethylcarbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0308] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-butylcarbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0309] quinoxaline-2-carboxylic acid [7-fluoro-1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl]-amide;

[0310] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(3,4-dichloro-benzyl)-7-fluoro-2(S)-hydroxy-7-methyl-octyl]-amide;

[0311] 7,8-difluoro-quinoline-3-carboxylic acid [4(R)-carbamoyl-1(S)-(3,4-dichloro-benzyl)-7-fluoro-2(S)-hydroxy-7-methyl-octyl]-amide;

[0312] quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-1(S)-phenethyl-octyl)-amide;

[0313] 7,8-difluoro-quinoline-3-carboxylic acid [4(R)-carbamoyl-7-fluoro-1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide;

[0314] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-7-fluoro-1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide;

[0315] quinoxaline-2-carboxylic acid {1(S)-[4(R)-(3-methyl-butyl)-5-oxo-tetrahydro-furan-2-yl]-2(S)-phenyl-ethyl}-amide;

[0316] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(4-methyl-piperazine-1-carbonyl)-octyl]-amide;

[0317] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-(tetrahydro-pyran-4(R)-yl)-pentyl]-amide;

[0318] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(piperidine-1-carbonyl)-octyl]-amide;

[0319] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(morpholine-4(R)-carbonyl )-octyl]-amide;

[0320] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(3-morpholin-4-yl-propionyl)-octyl]-amide;

[0321] quinoxaline-2-carboxylic acid [1(S)-benzyl-3-(2-carbamoyl-indan-2-yl)-2(S)-hydroxy-propyl]-amide;

[0322] quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-4(R)-methylcarbamoyl-7-phenyl-hept-6-enyl)-amide;

[0323] quinoline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0324] 6,7-dihydro-5H-[1 ]pyrindine-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0325] quinoxaline-2-carboxylic acid (1(S)-benzyl-4-carbamoyl-4(S)-cyclohexyl-2(S)-hydroxy-butyl)-amide;

[0326] quinoxaline-2-carboxylic acid (1(S)-benzyl-4-carbamoyl-4(S)-cyclohexyl-2(S)-hydroxy-butyl)-amide;

[0327] quinoxaline-2-carboxylic acid (1(S)-benzyl-4-carbamoyl-4(S)-cyclohexyl-2(S)-hydroxy-butyl)-amide;

[0328] quinoxaline-2-carboxylic acid (1(S)-benzyl-4-carbamoyl-4(S)-cyclopentyl-2(S)-hydroxy-butyl)-amide;

[0329] quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0330] N-1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-5-bromo-nicotinamide;

[0331] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1-(2(S)-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide;

[0332] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-I (S)-(2(S)-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide;

[0333] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-4(S)-(4-isopropyl-cyclohexyl)-butyl]-amide;

[0334] quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-1(S)-thiophen-2-ylmethyl-octyl)-amide;

[0335] quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-1(S)-thiazol-4(R)-ylmethyl-octyl)-amide;

[0336] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4(S)-(3,3,5,5-tetramethyl-cyclohexyl)-butyl]-amide;

[0337] quinoxaline-2-carboxylic acid (1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4(S)-indan-2-yl-butyl)-amide;

[0338] quinoxaline-2-carboxylic acid (1(S)-benzyl-4(S)-carbamoyl-4(S)-cycloheptyl-2(S)-hydroxy-butyl)-amide;

[0339] quinoxaline-2-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-propyl-octyl)-amide;

[0340] quinoxaline-2-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-propyl-oct-5-enyl)-amide;

[0341] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2,7-dihydroxy-7-methyl-octyl)-amide;

[0342] quinoxaline-2-carboxylic acid 1(S)-benzyl-7-chloro-2(S)-hydroxy-4(R)-methylcarbamoyl-hept-6-enyl)-amide;

[0343] quinoxaline-2-carboxylic acid 1(S)-benzyl-7-chloro-2(S)-hydroxy-4(R)-methylcarbamoyl-hept-6-enyl)-amide;

[0344] quinoxaline-2-carboxylic acid 1(S)-benzyl-6-chloro-2(S)-hydroxy-4(S)-methylcarbamoyl-hept-6-enyl)-amide;

[0345] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-6-chloro-2(S)-hydroxy-hept-6-enyl)-amide;

[0346] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-6-cyclopropyl-2(S)-hydroxy-hexyl)-amide;

[0347] quinoxaline-2-carboxylic acid 1(S)-benzyl-6-cyclopropyl-2(S)-hydroxy-4(R)-methylcarbamoyl-hexyl)-amide;

[0348] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-4(S)-(4-methyl-cyclohexyl)-butyl]-amide;

[0349] quinoxaline-2-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-4(S)-indan-2-yl-butyl)-amide;

[0350] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-(4-trifluoromethoxy-phenyl)-pentyl]-amide;

[0351] quinoxaline-2-carboxylic acid [1-benzyl-4(R)-carbamoyl-5-(4-fluoro-phenyl)-2(S)-hydroxy-pentyl]-amide;

[0352] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-chloro-2(S)-hydroxy-hept-6-enyl)-amide;

[0353] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-chloro-2(S)-hydroxy-hept-6-enyl)-amide;

[0354] 3-Hydroxy-quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0355] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-benzylcarbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0356] quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-[(pyridin-3-ylmethyl)-carbamoyl]-octyl}-amide;

[0357] quinoxaline-2-carboxylic acid 1(S)-benzyl-8,8-trifluoro-2(S)-hydroxy-4(R)-methylcarbamoyl-7-trifluoromethyl-octyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-8,8-trifluoro-2(S)-hydroxy-7-trifluoromethyl-octyl)-amide;

[0358] quinoxaline-2-carboxylic acid [2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-1(S)-(4-methylcarbamoyl-benzyl)-octyl]-amide;

[0359] quinoxaline-2-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-5-ethyl-2(S)-hydroxy-heptyl)-amide;

[0360] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4(S)-(tetrahydro-pyran-4-yl)-butyl]-amide;

[0361] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(2(R)-pyridin-2-yl-ethylcarbamoyl )-octyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-(3,4-dimethoxy-benzylcarbamoyl)-7-fluoro-2(S)-hydroxy-7-methyl-octyl]-amide;

[0362] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-6-methoxy-hexyl)-amide;

[0363] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-chloro-2(S)-hydroxy-oct-6-enyl)-amide;

[0364] quinoxaline-2-carboxylic acid 1(S)-benzyl-7-chloro-2(S)-hydroxy-4(R)-methylcarbamoyl-oct-6-enyl)-amide;

[0365] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-4(S)-(3,5-dimethyl-cyclohexyl)-2(S)-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-[(pyridin-2-ylmethyl)-carbamoyl]-octyl}-amide;

[0366] quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2-(4-hydroxy-phenyl)-ethylcarbamoyl]-7-methyl-octyl}-amide;

[0367] quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-[(thiophen-2-ylmethyl)-carbamoyl]-octyl}-amide;

[0368] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-6-phenoxy-hexyl)-amide;

[0369] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-6-isopropoxy-hexyl)-amide; quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-octyl}-amide;

[0370] quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-[(pyridin-4-ylmethyl)-carbamoyl]-octyl}-amide;

[0371] quinoxaline-2-carboxylic acid [1(S)-benzyl-4-(2-ethylsulfanyl-ethylcarbamoyl)-7-fluoro-2(S)-hydroxy-7-methyl-octyl]-amide;

[0372] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-(2-methoxy-ethylcarbamoyl)-7-methyl-octyl]-amide;

[0373] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(2-pyridin-3-yl-ethylcarbamoyl)-octyl]-amide;

[0374] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(2-pyridin-4(R)-yl-ethylcarbamoyl)-octyl]-amide;

[0375] quinoxaline-6-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0376] quinoxaline-2-carboxylic acid 1(S)-benzyl-6-tert-butoxy-4(R)-carbamoyl-2(S)-hydroxy-hexyl)-amide;

[0377] quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-[2-1(S)-methyl-1H-pyrrol-2-yl)-ethylcarbamoyl]-octyl}-amide;

[0378] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-4-(1,1-dioxo-hexahydro-thiopyran-4-yl)-2(S)-hydroxy-butyl]-amide;

[0379] quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2-(6-methoxy-1H-indol-3-yl)-ethylcarbamoyl]-7-methyl-octyl}-amide;

[0380] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-(2-methoxy-benzylcarbamoyl)-7-methyl-octyl]-amide;

[0381] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-(3-methoxy-benzylcarbamoyl)-7-methyl-octyl]-amide;

[0382] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(2-thiophen-2-yl-ethylcarbamoyl)-octyl]-amide;

[0383] quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2-(1H-indol-3-yl)-ethylcarbamoyl]-7-methyl-octyl}-amide;

[0384] quinoxaline-2-carboxylic acid {4(R)-[2-(4-amino-phenyl)-ethylcarbamoyl]-1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl}-amide;

[0385] quinoxaline-2-carboxylic acid {1(S)-benzyl-4(R)-[2-(3,5-dimethoxy-phenyl)-ethylcarbamoyl]-7-fluoro-2(S)-hydroxy-7-methyl-octyl}-amide;

[0386] quinoxaline-2-carboxylic acid {1(S)-benzyl-4(R)-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-7-fluoro-2(S)-hydroxy-7-methyl-octyl}-amide;

[0387] quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-4(R)-[(furan-2-ylmethyl)-carbamoyl]-2(S)-hydroxy-7-methyl-octyl}-amide;

[0388] quinoxaline-2-carboxylic acid {1(S)-benzyl-4(R)-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-7-fluoro-2(S)-hydroxy-7-methyl-octyl}-amide;

[0389] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-(4-methoxy-benzylcarbamoyl)-7-methyl-octyl]-amide;

[0390] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-6-cyclohexyloxy-2(S)-hydroxy-hexyl)-amide;

[0391] quinoxaline-2-carboxylic acid {4(R)-[(1H-benzoimidazol-2-ylmethyl)-carbamoyl]-1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl}-amide;

[0392] quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-(2(S)-hydroxymethyl-pyrrolidine-1-carbonyl)-7-methyl-octyl]-amide;

[0393] quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-[(tetrahydrofuran-2-ylmethyl)-carbamoyl]-octyl}-amide;

[0394] quinoxaline-2-carboxylic acid [1(S)-benzyl-4-carbamoyl-4(S)-(4,4-difluoro-cyclohexyl)-2(S)-hydroxy-butyl]-amide;

[0395] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-(2,3-dimethoxy-benzylcarbamoyl)-7-fluoro-2(S)-hydroxy-7-methyl-octyl]-amide;

[0396] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-cyclohexyl)-butyl]-amide;

[0397] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-4-(2,6-dimethyl-tetrahydro-pyran-4-yl)-2(S)-hydroxy-butyl]-amide;

[0398] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-7-fluoro-1(S)-(3-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide;

[0399] 7,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0400] N-1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-5,6-dichloro-nicotinamide;

[0401] benzofuran-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0402] cinnoline-4(R)-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0403] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-1-(4-iodo-benzyl)-7-methyl-octyl]-amide;

[0404] pyrazine-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0405] 6,7,8-trifluoro-quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0406] quinoline-6-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0407] isoquinoline-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0408] 2-methoxy-quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0409] 1H-benzoimidazole-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0410] benzothiazole-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0411] 5-methyl-pyrazine-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0412] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-pyridin-3-yl-pentyl)-amide;

[0413] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-cyclohexyl)-butyl]-amide;

[0414] quinoline-3-carboxylic acid (1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-butyl)-amide;

[0415] quinoline-2-carboxylic acid (1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-butyl)-amide;

[0416] fluoro-quinoline-3-carboxylic acid (1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-butyl)-amide;

[0417] N-(1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-butyl)-5,6-dichloro-nicotinamide;

[0418] N-(1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-butyl)-5-bromo-nicotinamide;

[0419] quinoxaline-2-carboxylic acid (4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-1-phenyl-octyl)-amide;

[0420] quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-pyridin-2-yl-pentyl)-amide;

[0421] quinoxaline-2-carboxylic acid [4(R)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-cyclohexyl)-1(S)-thiophen-2-ylmethyl-butyl]-amide;

[0422] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(4-hydroxy-tetrahydro-thiopyran-4-yl)-butyl]-amide;

[0423] 1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide;

[0424] quinoxaline-2-carboxylic acid (1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-hydroxycarbamoyl-7-methyl-octyl)-amide;

[0425] quinoxaline-2-carboxylic acid (1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-methoxycarbamoyl-7-methyl-octyl)-amide;

[0426] 7,8-difluoro-quinoline-3-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl-pentyl)-amide;

[0427] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-5-(2-chloro-phenyl)-2(S)-hydroxy-pentyl]-amide;

[0428] quinoxaline-2-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-o-tolyl-pentyl)-amide;

[0429] quinoxaline-2-carboxylic acid (1(S)-benzyl-2(S)-hydroxy-4(R)-hydroxycarbamoyl-5-phenyl-pentyl)-amide;

[0430] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-cyclopentyl)-butyl]-amide;

[0431] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0432] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-5-(3,4-dichloro-phenyl)-2(S)-hydroxy-pentyl]-amide;

[0433] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-5-(2-fluoro-phenyl)-2(S)-hydroxy-pentyl]-amide;

[0434] quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4-(1-hydroxy-cyclopentyl)-butyi]-amide;

[0435] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-3-methyl-cyclopentyl)-butyl]-amide;

[0436] quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[0437] N-(1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl-pentyl)-5-bromo-nicotinamide;

[0438] 8-Fluoro-quinoline-3-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl-pentyl)-amide;

[0439] 6,7-dihydro-5H-[1 ]pyrindine-3-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl-pentyl)-amide;

[0440] quinoline-3-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl-pentyl)-amide;

[0441] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-3,5-dimethyl-cyclohexyl)-butyl]-amide;

[0442] quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4-(1-hydroxy-3,5-dimethyl-cyclohexyl)-butyl]-amide;

[0443] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-cycloheptyl)-butyl]-amide;

[0444] quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4-(1-hydroxy-cycloheptyl)-butyl]-amide;

[0445] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-5-(3-fluoro-phenyl)-2(S)-hydroxy-pentyl]-amide;

[0446] quinoxaline-2-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-m-tolyl-pentyl)-amide;

[0447] quinoxaline-2-carboxylic acid (1(S)-benzyl-2(S)-hydroxy-4-isobutylcarbamoyl-butyl)-amide;

[0448] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(2-hydroxy-adamantan-2-yl)-butyl]-amide;

[0449] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(9-hydroxy-bicyclo[3.3.1 ]non-9-yl)-butyl]-amide;

[0450] quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-(2-hydroxy-adamantan-2-yl)-4-hydroxycarbamoyl-butyl]-amide;

[0451] quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-(9-hydroxy-bicyclo[3.3.1 ]non-9-yl)-4-hydroxycarbamoyl-butyl]-amide;

[0452] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-(3-methoxy-phenyl)-pentyl]-amide;

[0453] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-4-propyl-cyclohexyl)-butyl]-amide;

[0454] quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4-(1-hydroxy-4-propyl-cyclohexyl)-butyl]-amide;

[0455] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-(4-methoxy-phenyl)-pentyl]-amide;

[0456] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-4(S)-(4-ethyl-1-hydroxy-cyclohexyl)-2-hydroxy-butyl]-amide;

[0457] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-4,4-dimethyl-cyclohexyl)-butyl]-amide;

[0458] quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4-(1-hydroxy-4,4-dimethyl-cyclohexyl )-but yl]-amide;

[0459] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-4-(4,4-difluoro-1-hydroxy-cyclohexyl)-2-hydroxy-butyl]-amide;

[0460] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-(4,4-difluoro-1-hydroxy-cyclohexyl)-2(S)-hydroxy-4-hydroxycarbamoyl-but yl]-amide; and

[0461] quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-4-trifluoromethyl-cyclohexyl)-butyl]-amide.

[0462] The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis). in a mammal, preferably a human, comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.

[0463] The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting MIP-1α binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier. Examples of such disorders and conditions are those enumerated in the preceding paragraph.

[0464] The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.

[0465] The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.

[0466] The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0467] The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0468] The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention a CCR1 receptor antagonizing effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.

[0469] This invention also encompasses pharmaceutical compositions containing and methods of treating or preventing comprising administering prodrugs of compounds of the formula I. Compounds of formula I having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of compounds of formula I. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain. Prodrugs also include compounds of formula I in which the secondary amide and its β-hydroxy when taken together form a group of the formula 4

[0470] wherein R1, R2, R3, R4 and R5 are as defined in formula I and U and V are independently carbonyl, methylene, SO2 or SO3, and b is an integer from one to three wherein each methylene group is optionally substituted with hydroxy.

DETAILED DESCRIPTION OF THE INVENTION

[0471] Compounds of the formula I may be prepared according to the following reaction schemes and discussion. Unless otherwise indicated g, n, m, p, and R1 through R6 and structural formula I in the reaction Schemes and discussion that follow are as defined above. 5

[0472] Scheme 1 refers to the preparation of compounds of the formula I having the exact stereochemistry 6

[0473] Compounds of the formula Ia and Ib, or any of the intermediates thereof, can be separated by column chromatography according to methods well known to those of ordinary skill in the art, to yield pure compounds of the formula Ia and Ib.

[0474] Referring to Scheme 1, compounds of the formula I, wherein either or both R4 or R5 are other than hydrogen, are prepared from compounds of the formula II (i.e. IIa and IIb) by reaction with a compound of the formula R4R5NH in a polar solvent at a temperature from about 0° C. to about 100° C., preferably the boiling point of the solvent used, i.e. 65° C. when methanol is the solvent. Suitable solvents include, alcohols, such as methanol, ethanol, or butanols or ethers such as glyme or dioxane (an acid catalyst is preferably used with an ether solvent). Preferably the solvent is dioxane.

[0475] Alternatively, compounds of formula I, wherein either or both R4 and R5 are hydrogen, can be prepared from compounds of formula II, (i.e. IIa and IIb) by reaction with ammonia or another volatile amine in a polar solvent at a temperature from about −10° C. to about 35° C., preferably at about 30° C. Suitable solvents include, alcohols, such as methanol, ethanol, or butanols; or ethers such as glyme or dioxane (an acid catalyst may be used with an ether solvent). Preferably the solvent is methanol.

[0476] Compounds of formula II are prepared by coupling a compound of formula III (i.e. IIIa and IIIb) with an acid of the formula R1CO2H. Such a coupling reaction is generally conducted at a temperature of about −30° C. to about 80° C., preferably about 0° C. to about 25° C. Examples of suitable coupling reagents which activate the carboxylic acid functionality are dicyclohexylcarbodiimide/hydroxybenzotriazole (DCC/HBT), N-3-dimethylaminopropyl-N′-ethylcarbodiimide (EDC)/HBT, 2-ethyoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), carbonyl diimidazole (CDI)/dimethylaminopyridine (DMAP), and diethylphosphorylcyamide. The coupling is conducted in an inert solvent, preferably an aprotic solvent, such as acetonitirile, dichloromethane, chloroform, and dimethylformamide. The preferred solvent is dichloromethane.

[0477] For a discussion of other conditions used for amide coupling see Houben-Weyl, Vol. XV, part II, E. Wunsch, Ed., George Theime Veriag, 1974, Stuttgart, and those described in M. Bodanszky. Principles of Peptide Synthesis, Springer-Verlag, Berlin (1984) and The Peptides, Analysis, Synthesis and Biology (ed. E. Gross and J. Meienhofer), Vois 1-5. (Academic Press, New York) 1979-1983.

[0478] The compounds of formula III, wherein R3 is (C1-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n—, (C2-C9)heterocycloalkyl-(CH2)n—, (C2-C9)heteroaryl-(CH2)n—, or aryl-(CH2)n— can be prepared by deprotection of compounds of the formula IV (i.e. IVa and lVb). Suitable protecting groups, of the formula P, include carbobenzyloxy, t-butoxy carbonyl or 9-fluorenyl-methylenoxy carbonyl.

[0479] For example:

[0480] (a) If the protecting group, P, of the compound of the formula IV is carbobenzyloxy, the latter may be removed by hydrogenation with a nobel metal catalyst such as palladium or palladium hydroxide on carbon in the presence of hydrogen. The hydrogenation is generally conducted at a temperature of about 0° C. to about 100° C., preferably about 20° C. to 50° C.

[0481] (b) If the protecting group, P, is t-butoxycarbonyl group, such group may be removed by acidolysis. Acidolysis may be conducted with HCl in dioxane or with trifluoracetic acid in methylene chloride at a temperature of about −30° C. to about −70° C., preferably about −5° C. to about 35° C.

[0482] (c) If the protecting group, P, is 9-fluorenylmethylenoxycarbonyl, such group may be removed by treatment with an amine base, preferably piperidine. This reaction may be run in piperidine as solvent at 10° C. to about 100° C., preferably at 25° C.

[0483] Compounds of the formula III, wherein R3 is substituted (C1-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n— or (C2-C9)heterocycloalkyl-(CH2)n— may be prepared from compounds of the formula IV, wherein R3 is (C1-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n— or (C2-C9)heterocycloalkyl-(CH2)n—, wherein one of the carbon-carbon single bonds is replaced by a carbon-carbon double bond, by methods well known to those of ordinary skill in the art. Specifically, one example of introduction of substitution into the R3 group, a compound of formula III, wherein R3 is (C1-C10)alkyl substituted by one to three fluoro groups can be prepared from compounds of the formula IV, wherein R3 is (C1-C10)alkyl, wherein one of the carbon-carbon single bonds of said (C1-C10)alkyl has been replaced by a carbon-carbon double bond, by reaction with hydrogen fluoride in pyridine (i.e. pyridinium poly(hydrogen fluoride), in a reaction inert solvent. Suitable solvents include cyclohexane, toluene or benzene, preferably benzene. The aforesaid reaction is run at a temperature from about −78° C. to about 35° C. Preferably, this reaction is carried out in benzene at about 25° C.

[0484] Compounds of the formula IV, wherein R3 is (C1-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n—(C2-C9)heterocycloalkyl-(CH2)n—, (C2-C9)heteroaryl-(CH2)n— or aryl-(CH2)n—, wherein n is other than zero, can be prepared by reaction of a compound of formula V with a compound of the formula R3—L, wherein L is a leaving group, in the presence of a strong base in an aprotic polar solvent. Suitable leaving groups include chloro, fluoro, bromo, iodo, mesylate, triflate or tosylate. Preferably, the leaving group is a triflate, iodide or bromide. Triflates may be easily prepared according to the method of Beard, et al., J Org Chem., 38, 3673 (1973). Suitable bases include lithium dialkyl amides such as lithium N-isopropyl-N-cyclohexylamide or potassium hydride. Suitable solvents include ethers (such as THF, glyme or dioxane) benzene or toluene, preferably THF. The aforesaid reaction is conducted at about −78° C. to about 0° C., preferably at about −78° C.

[0485] Alternatively, compounds of the formula IV, wherein R3 is (C1-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n— or (C2-C9)heterocycloalkyl-(CH2)n— can be prepared by reaction of a compound of formula V with an aldehyde or ketone precursor of R3 in an aldol condensation. For example, a compound of the formula V can be reacted with a compound of the formula R3(═O) in the presence of a base, to form an aldol intermediate of the formula 7

[0486] which may be isolated and taken on to final product or converted directly in the same reaction step to a compound of the formula IV by the loss of water. The degree of completion for the conversion of compounds of the formula II to the aldol product of formula I may be assessed using one or more analytical techniques, such as thin layer chromatography (tlc) or mass spectrometry. In some instances it may be possible or desirable to isolate the intermediate of formula VI. In such case, the compound of formula VI may be converted into the compound of formula IV by the elimination of water using techniques which are familiar to those skilled in the art, for example, by heating to the reflux temperature a solution of the compound of formula VI in a solvent such as benzene, toluene or xylene, in the presence of a catalytic amount of phosphorous pentoxide, benzene- or p-toluene-sulfonic acid with provision for the removal of the water generated, preferably (methoxycarbonylsulfamoyl)-triethylammonium hydroxide (Burgess reagent). Such water removal techniques may involve the use of molecular sieves or a Dean-Stark trap to isolate the water created as an azeotrope with the solvent.

[0487] The aldol reaction is typically carried out in a polar solvent such as DMSO, DMF, tetrahydrofuran (THF), methanol or ethanol, at a temperature from about −78° C. to about 80° C. Preferably, this reaction is carried out in THF at about −78° C. Suitable bases for use in the aldol formation step include potassium carbonate (K2CO3), sodium carbonate (Na2CO3), sodium hydride (NaH), sodium methoxide, potassium-tert.-butoxide, lithium diisopropylamide, pyrrolidine and piperidine. Lithium diisopropylamide is preferred. Aldol condensations are described in “Modern Synthetic Reactions,” Herbert O. House, 2d. Edition, W. A. Benjamin, Menlo Park, Calif., 629-682 (1972), J. Org. Chem., 49, 2455 (1984), and Tetrahedron, 38 (20), 3059 (1982).

[0488] Compounds of the formula IV wherein R3 is unsaturated can be converted to saturated analogues by hydrogenating the compounds containing a carbon-carbon double bond, using standard techniques that are well known to those skilled in the art. For example, reduction of the double bond may be effected with hydrogen gas (H2), using catalysts such as palladium on carbon (Pd/C), palladium on barium sulfate (Pd/BaSO4), platinum on carbon (Pt/C), or tris(triphenylphosphine) rhodium chloride (Wilkinson's catalyst), in an appropriate solvent such as methanol, ethanol, THF, dioxane or ethyl acetate, at a pressure from about 1 to about 5 atmospheres and a temperature from about 10° C. to about 60° C., as described in Catalytic Hydrogenation in Organic Synthesis, Paul Rylander, Academic Press Inc., San Diego, 31-63 (1979). The following conditions are preferred: Pd on carbon, methanol at 25° C. and 50 psi of hydrogen gas pressure. This method also provides for introduction of hydrogen isotopes (Le deuterium, tritium) by replacing 1H2 with 2H2 or 3H2 in the above procedure.

[0489] An alternative procedure employing the use of reagents such as ammonium formate and Pd/C in methanol at the reflux temperature under an inert atmosphere (e.g., nitrogen or argon gas) is also effective in reducing the carbon-carbon double bond of compounds of the formula I. Another alternative method involves selective reduction of the carbon-carbon bond. This can be accomplished using samarium and iodine or samarium iodide (Sml2) in methanol or ethanol at about room temperature, as described by R. Yanada et. al., Synlett., 443-4 (1995).

[0490] Compounds of the formula V can be prepared by methods well known to those of ordinary skill in the art or are commercially available. Specifically, compounds of the formula Va and Vb (shown below) can be prepared by the method of Fray et al., (J. Org. Chem., 51, 4828-4833 (1986)) using an (S)-aldehyde of the formula 8

[0491] Compounds of the formula VII are prepared by reducing amino acids or amino esters to alcohols (Stanfield et al., J. Org. Chem. 46, 4799-4800 (1981), Soai et al., Bull. Chem. Soc. Jpn., 57, 2327 (1984)) followed by oxidation of the alcohols to aldehydes of the formula VII (Luly et al., J.Orq. Chem., 53 (26), 6109-6112 (1988) and Denis et al., J Orq. Chem., 56 (24), 6939-6942 (1991).). Un-natural amino acids can be prepared according to the method of Myers et al., Tet. Lett. 36, (1995) and Myers et al. J. Am. Chem. Soc., 117, 8488-8489 (1995).

[0492] Alternatively, compounds of the formula V can also be made by the method of DeCamp et al., (Tetrahedron Lett., 32, 1867 (1991)).

[0493] Compounds of the formula I, with the exact stereochemistry 9

[0494] can be prepared according to the methods of Scheme 1, using either the minor lactone diastereomer of the formula, 10

[0495] which can be prepared by the method of Fray, supra, from the (S)-aldehyde, or the alternate diastereomeric pair of the formula 11

[0496] which can be prepared using the corresponding (R)-aldehyde according to the method of Fray, supra.

[0497] Aldehyde or ketone precursors of the group R3 are commercially available (e.g., -cyclohexanone) or can be made by methods well known to those of ordinary skill in the art, such as described in J. Am. Chem. Soc., 90, 7001 (1968) and J. Ore. Chem., 40, 574 (1975).

[0498] Unless indicated otherwise, the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).

[0499] The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.

[0500] The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

[0501] Those compounds of the formula I which are also acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.

[0502] Compounds of the formula I and their pharmaceutically acceptable salts (hereinafter also referred to, collectively, as “the active compounds”) are potent antagonists of the CCR1 receptors. The active compounds are useful in the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis).

[0503] The activity of the compounds of the invention can be assessed according to procedures know to those of ordinary skill in the art. Examples of recognized methods for determining CCR1 induced migration can be found in Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., Strober, W. editors: Current Protocols In Immunology, 6.12.1-6.12.3. (John Wiley and Sons, NY, 1991). One specific example of how to determine the activity of a compound for inhibiting migration is described in detail below.

Chemotaxis Assay

[0504] The ability of compounds to inhibit the chemotaxis to various chemokines can be evaluated using standard 48 or 96 well Boyden Chambers with a 5 micron polycarbonate filter. All reagents and cells can be prepared in standard RPMI (BioWhitikker Inc.) tissue culture medium supplemented with 1 mg/ml of bovine serum albumin. Briefly, MIP-1α (Peprotech, Inc., P.O. Box 275, Rocky Hill N.J.) or other test agonists, were placed into the lower chambers of the Boyden chamber. A polycarbonate filter was then applied and the upper chamber fastened. The amount of agonist chosen is that determined to give the maximal amount of chemotaxis in this system (e.g., 1 nM for MIP-1α should be adequate).

[0505] THP-1 cells (ATCC TIB-202), primary human monocytes, or primary lymphocytes, isolated by standard techniques can then be added to the upper chambers in triplicate together with various concentrations of the test compound. Compound dilutions can be prepared using standard serological techniques and are mixed with cells prior to adding to the chamber.

[0506] After a suitable incubation period at 37 degrees centigrade (e.g. 3.5 hours for THP-1 cells, 90 minutes for primary monocytes), the chamber is removed, the cells in the upper chamber aspirated, the upper part of the filter wiped and the number of cells migrating can be determined according to the following method.

[0507] For THP-1 cells, the chamber (a 96 well variety manufactured by Neuroprobe) can be centrifuged to push cells off the lower chamber and the number of cells can be quantitated against a standard curve by a color change of the dye fluorocein diacetate.

[0508] For primary human monocytes, or lymphocytes, the filter can be stained with Dif Quik® dye (American Scientific Products) and the number of cells migrating can be determined microscopically.

[0509] The number of cells migrating in the presence of the compound are divided by the number of cells migrating in control wells (without the compound). The quotant is the % inhibition for the compound which can then be plotted using standard graphics techniques against the concentration of compound used. The 50% inhibition point is then determined using a line fit analysis for all concentrations tested. The line fit for all data points must have an coefficient of correlation (R squared) of >90% to be considered a valid assay.

[0510] All of the compounds of the invention that were tested had IC 50 of less than 25 μM, in the Chemotaxis assay.

[0511] The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation. The active compounds of the invention may also be formulated for sustained delivery.

[0512] For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).

[0513] For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner.

[0514] The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0515] The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

[0516] For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

[0517] A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., rheumatoid arthritis) is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.

[0518] Aerosol formulations for treatment of the conditions referred to above (e.g., rheumatoid arthritis) in the average adult human are preferably arranged so that each metered dose or “puff” of aerosol contains 20 μg to 1000 μg of the compound of the invention. The overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

[0519] The active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in U.S. Pat. Nos. 3,538,214, 4,060,598, 4,173,626, 3,119,742, and 3,492,397.

[0520] The compounds of the invention can also be utilized in combination therapy with other therapeutic agents such as with T-cell immunosuppressant agents such as cyclosporin A and FK-506, with steroid sparing agents such as Cellcept), or with classical anti-inflammatory agents (e.g. cyclooxygenase/lipoxegenase inhibitors) such as tenidap, aspirin, acetaminophen, naproxen and piroxicam.

[0521] The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million (6) and are referenced to the deuterium lock signal from the sample solvent (deuteriochloroform unless otherwise specified). Commercial reagents were utilized without further purification. THF refers to tetrahydrofuran. DMF refers to N,N-dimethylformamide. Chromatography refers to column chromatography performed using 32-63 mm silica gel and executed under nitrogen pressure (flash chromatography) conditions. Low Resolution Mass Spectra (LRMS) were recorded on either a Hewlett Packard 5989(, utilizing chemical ionization (ammonium), or a Fisons (or Micro Mass) Atmospheric Pressure Chemical Ionization (APCI) platform which uses a 50/50 mixture of acetonitrile/water with 0.1% formic acid as the ionizing agent. Room or ambient temperature refers to 20-25° C. All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields. Concentration at reduced pressure means that a rotary evaporator was used. The names for the compounds of the invention were created by the Autonom 2.0 PC-batch version from Beilstein Informationssysteme GmbH (ISBN 3-89536-976-4).

EXAMPLE 1

[0522] Quinoline-3-carboxylic Acid (1(S)-Cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl-6-enyl)-amide

Method A

[0523] Quinoline-3-carboxylic Acid {1-[4-(2-methylpropen-2-yl)-5-oxo-tetrahydrofuran-2-yl]-2-cyclohexyl-ethyl}-amide

[0524] To a solution of 1-{4-(2-methylpropen-2-yl)-[5-oxo-tetrahydrofuran-2-yl]-2-cyclohexyl-ethyl}-carbamic acid tert-butyl ester (302 mg, 0.83 mmol)(prepared according to the method of Fray, supra, except that (S)-2-(tert-butoxycarbonylamino)-3-cyclohexyl-1-propionaldehyde is the starting material aldehyde) in 15 mL of methylene chloride was added 1.5 mL of trifluoroacetic acid. The mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours at which time the solvent was removed by azeotropic distillation under reduced pressure, using toluene as a cosolvent during the distillation. The resulting crude oil was dissolved in methylene chloride (5 mL) and quinoline-3-carboxylic acid (219 mg, 1.26 mmol), hydroxybenzotriazole (HOBT)(188 mg, 1.39 mmol), triethylamine (0.25 mL, 1.80 mmol) and N-3-dimethylaminopropyl-N′-ethylcarbodiimide (EDC)(248 mg, 1.29 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours. The solution was transferred to a separatory funnel with 15 mL of methylene chloride and washed with 10% citric acid, saturated sodium bicarbonate and brine. The organic layer was dried over sodium sulfate and the solvent removed in vacuo. The remaining crude oil was purified by silica gel chromatography eluting with 3:1 hexanes:ethyl acetate to provide quinoline-3-carboxylic acid {1(S)-[4(R)-(2-methylpropen-2-yl)-5-oxo-tetrahydrofuran-2(S)-yl]-2-cyclohexyl-ethyl}-amide as a white foam (236 mg, 67%).

[0525] LRMS: 421 (MH+); 1H NMR(300 MHz, CDCl3): δ 0.90-1.89 (m, 13H), 1.63 (s, 3H), 2.03-2.14 (m, 2H), 2.38 (m, 2H), 2.48 (d, 1H, J=14.6 Hz), 2.73 (m, 1H), 4.63 (m, 2H), 4.69 (s, 1H), 4.79 (s, 1H), 6.9 (brs, 1H), 7.59 (t, 1H, J=7.8 Hz), 7.77 (t, 1H, J=8.4 Hz), 7.88 (d, 1H, J=8.3 Hz), 8.08 (d, 1H, J=8.4 Hz), 8.67 (s, 1H), 9.37 (d, 1H, J=2.1 Hz).

Method B

[0526] Quinoline-3-carboxylic Acid (1(S)-Cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-heptyl-6-enyl)-amide

[0527] Methylamine was bubbled into a solution of the product from Method A (55 mg, 0.129 mmol) in methanol (2.5 mL). The solution was stirred for 2 hours at room temperature and the solvent was removed under reduced pressure to provide the title compound (57 mg, 98%) as a pure white solid.

[0528] LRMS: 453 (MH+), 421, 283, 173; 1H NMR (300 MHz, CDCl3): δ 0.82-1.87 (m, 13H), 1.65 (s, 3H), 2.13 (dd, 1H, J=14.1, 8.7 Hz), 2.38 (d, 1H, J=14.2 Hz), 2.71 (d, 3H, J=4.7 Hz), 2.74 (m, 1H), 3.77 (d, 1H, J=8.7), 4.23 (br, 1H), 4.69 (s, 1H), 4.72 (s, 1H), 5.03 (brs, 1H), 6.60 (q, 1H, J=4.7 Hz), 7.24 (d, 1H, J=9.3), 7.54 (t, 1H, J=7.1), 7.73 (t, 1H, J=7.1 Hz), 7.81 (d, 1H, J=7.1 Hz), 8.04 (d, 1H, J=8.4), 8.61 (d, 1H, J=1.9), 9.33 (s, 1H).

EXAMPLE 2

[0529] Quinoxaline-2-carboxylic Acid (1(S)-Benzyl-4(R)-benzylcarbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide

Allylic Alkylation

Method C

[0530] {1(S)-[4(R)-(3-Methyl-but-2-enyl)-5-oxo-tetrahydro-furan-2(S)-yl]-1-2-phenyl-ethyl}-carbamic Acid Tert-Butyl Ester

[0531] To a flame dried round bottom flask under a nitrogen atmosphere was added tetrahydrofuran (40 mL) followed by 1,1,1,3,3,3-hexamethyldisilazane (8 mL, 37.8 mmol). The mixture was cooled to 0° C. and n-butyl lithium (14.5 mL of a 2.5 M solution in hexanes, 36.0 mmol) was added. The mixture was stirred for 15 minutes, then cooled to −78° C. in dry ice/acetone bath. {1(S)-[5-Oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester (5 g, 16.4 mmol) (prepared by the method of Fray, J. Org. Chem., (51) 4828 (1986)) dissolved in tetrahydrofuran (50 mL) was added dropwise via syringe and stirring continued for 30 minutes. A solution of 4-bromo-2-methyl-2-butene (2.07 mL, 18.0 mmol) in 40 mL of THF was added dropwise via syringe. Stirring was continued for 3 hours during which time the temperature rose to −60° C. The mixture was quenched by slow addition of saturated, aqueous ammonium chloride (25 mL). Upon warming to room temperature, the solution was diluted with ether (300 mL) and transferred to a separatory funnel. The organic phase was washed with saturated aqueous citric acid (2×100 mL), saturated aqueous sodium bicarbonate (NaHCO3)(2×100 mL), and 100 mL brine. The organic layer was dried over magnesium sulfate (MgSO4) and the solvent removed under reduced pressure. Thin layer chromatography in 1:2 hexane/diethyl ether (Et2O) revealed product with an Rf of 0.8. The resulting crude oil was chromatographed on silica gel (225 g) eluting with 2:1 hexanes/diethyl ether to provide 4.73 g (77%) of the title compound. TLC: 1:2 Hexanes/Et2O Rf: 0.8. 1H NMR (400 MHz, CDCl3): δ 7.27 ppm (5H, m), 5.02 (1H, b), 4.52 (1H, d, J=9.3 Hz), 4.42 (1H, t, J=7.1 Hz), 3.98 (1H, dt, J=8.5, 7.8 Hz), 2.93 (2H, m), 2.88 (1H, b), 2.68 (1H, m), 2.41 (1H, m), 2.24 (1H, m), 1.92 (1H, m), 1.65 (3H, s), 1.58 (3H, s), 1.37 (9H, s).

Method D

[0532] 5(S)-(1(S)-Amino-2-phenyl-ethyl)-3(R)-(3-fluoro-3-methyl-butyl)-dihydro-furan-2-one

[0533] To a solution of product from Method C (9.81 g, 26.3 mmol) in dry benzene (300 mL) was added HF-pyridine (88 mL). The resulting solution was stirred at ambient temperature for 4 hours, then transferred to a 4 L beaker. To this was added ice, and the pH was slowly adjusted to 8-9 by addition of 2 M aqueous sodium hydroxide (NaOHaq). The mixture was extracted with ethyl acetate (EtOAc) and the organics dried over magnesium sulfate, and then filtered and concentrated. Chromatography on silica gel yielded the title compound (5.68 g, 74%).

Method E

[0534] Quinoxaline-2-carboxylic Acid {1(S)-[4(R)-(3-fluoro-3-methyl-butyl)-5-oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-amide

[0535] To a solution of quinoxaline carboxylic acid (5.05 g, 29.0 mmol) in methylene chloride (100 mL) was added dimethylaminopyridine (DMAP) (3.55 g, 29.0 mmol) and EDCI (5.55 g, 29.0 mmol). The solution was stirred 10 minutes, then the product from Method D, above, (5.68 g, 19.4 mmol) was added in one portion. The solution was stirred for 12 hours, then diluted with diethyl ether and washed with saturated aqueous brine. The organics were dried over magnesium sulfate, and then filtered and concentrated. The crude product was purified by silica gel chromatography to yield the title compound (5.62 g, 64%).

Method F

[0536] Quinoxaline-2-carboxylic Acid (1(S)-Benzyl-4(R)-benzylcarbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide

[0537] To a solution of the product from Method E (0.10 g, 0.22 mmol) in dioxane (2 mL) was added glacial acetic acid (0.038 mL, 0.66 mmol) and benzylamine (approx. 1 mL, excess). The resulting solution was warmed to reflux for 1 hour, cooled to ambient temperature and diluted with water. The solution was extracted with ethyl acetate and the combined organics were dried over magnesium sulfate (MgSO4), filtered and concentrated. Chromatography on silica gel, followed by recrystallization from methylene chloride/hexanes gave the title compound (0.068 g, 56%). m.p. 183-184° C.

EXAMPLE 3

Method F′

[0538] Quinoxaline-2-carboxylic Acid (1-benzyl-7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-octyl)-amide

[0539] Hydroxylamine hydrochloride (1.55 g, 22.4 mmol) and KOH (1.51 g, 26.7 mmol) were combined in anhydrous methanol (20 mL) and stirred for 30 minutes under a dry nitrogen atmosphere, and then filtered. To the resulting filtrate was added the product from Method E (500 mg, 1.17 mmol) and the reaction mixture was stirred for 16 hours at room temperature. The solvent was removed in vacuo and the residue solvated in EtOAc (50 mL) and transferred to a separated funnel. The organic layer was washed with water and brine and dried (MgSO4). After filtration the solvent was removed in vacuo and the remaining residue recrystallized (methylene chloride/Hexanes) to give a pale yellow solid (330 mg, 58%) m.p. 165-166° C.

EXAMPLE 4

[0540] Quinoxaline-2-carboxylic Acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl-octyl)-amide

METHOD G

Alkene Hydrogenation

[0541] {1(S)-[4(R)-(3-Methyl-butyl)-5-oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic Acid Tert-Butyl Ester

[0542] The product from Method C, from Example 2 above, (3.0 g, 8.04 mmol) was placed in a 250 mL Parr Shaker bottle and dissolved in ethanol (50 mL). Under a nitrogen atmosphere, Palladium (Pd) on activated carbon (0.30 g, 10% Pd content) was added to the solution. The mixture was placed on a Parr Shaker hydrogenator at 50 psi for 5 hours at room temperature. The hydrogenation mixture was diluted with ethyl acetate and then poured through a Celite® pad while washing copiously with ethyl acetate. The solvent of the filtrate was removed in vacuo to yield the title compound, 2.63 g (88%).

[0543] 1 H NMR (400 MHz, CDCl3): δ 7.27 (5H, m), 4.54 (1H, d, J=9.8 Hz), 4.46 (1H, t, J=6.9), 4.0 (1H, dt), 2.89 (2H, d, J=8.1), 2.57 (1H, m), 2.32 (1H, b), 1.89 (1H, m), 1.79 (1H, m), 1.52 (2H, m), 1.37 (9H, s), 1.23 (2H, m), 0.86 (6H, d, J=6.6 Hz).

[0544] The product from Method G was converted into the title compound by procedures analogous to those of Methods A and B except that quinoline-3-carboxylic acid is replaced with quinoxaline-2-carboxylic acid and methylamine is replaced with ammonia gas to yield 0.095 g (72%) of the title compound.

[0545] 1 H NMR (400 MHz, CDCl3): δ 9.61(1H, s), 8.32 (1H, d, J=8.9 Hz), 8.16 (2H, m), 7.86 (2H, m), 7.28 (10H, m), 7.19 (1H, m), 5.70 (1H, b), 5.29 (1H, b), 4.27 (1H, m), 8.21 (1H, d, J=4.4 Hz), 3.91 (1H, m), 3.11 (2H, m), 2.46 (1H, m), 1.74 (1H, t, J=6.4 Hz), 1.61 (1H, m), 1.42 (2H, m), 1.17 (1H, m), 1.09 (1H, m), 0.81 (3H, d, J=7.1 Hz), 0.79 (3H, d, J=7.1 Hz). 13C NMR (100 MHz, CDCl3):d 179.11, 163.73, 143.90, 143.76, 143.15, 140.28, 137.96, 131.68, 130.84, 129.84, 129.44, 129.25, 128.58, 126.60, 68.55, 55.90, 43.44, 38.39, 36.90, 36.70, 29.77, 28.03, 22.42

EXAMPLE 5

[0546] Quinoxaline-2-carboxylic Acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7.7-dimethyl-octyl)-amide

Method H

Triflate Alkylation

[0547] {-[4-(3,3-Dimethyl-butyl)-5-oxo-tetrahydro-furan-2-yl]-2-phenyl-ethyl)-carbamic Acid Tert-Butyl Ester

[0548] To a flame dried round bottom flask under a nitrogen atmosphere was added terahydrofuran (THF) (2 mL) and 1,1,1,3,3,3 hexamethyldisilazane (0.82 mL, 3.88 mmol). The mixture was cooled to 0° C. and n-butyl lithium (1.48 mL of a 2.5 M solution in hexanes, 3.72 mmol) was added dropwise via syringe. The mixture was stirred for 15 minutes and then cooled to −78° C. {1(S)-[5-Oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester (0.52 9, 1.69 mmol prepared by the method of Fray, supra) dissolved in tetrahydrofuran (2 mL) was slowly added to the solution via syringe and the solution was stirred for 1 hour. A solution of the desired triflate, i.e. 3,3-dimethylbutyl triflate (0.92 g, 3.37 mmol)(prepared according to the method of Beard, et al., J Orq Chem., 38, 3673 (1973)) in tetrahydrofuran (2 mL) was added dropwise via syringe and the mixture was stirred for 2 hours at −78° C. The mixture was quenched by addition of saturated aqueous ammonium chloride (NH4Cl) (25 mL). Upon warming to room temperature, the mixture was diluted with ethyl acetate (40 mL), transferred to a separatory funnel, and washed with saturated aqueous NH4Cl (2×40 mL), saturated NaHCO3 (2×40 mL), and brine (40 mL). The organic layers were dried (MgSO4) and the solvent removed under reduced pressure. The resulting crude oil was chromatographed on silica gel (25 g) eluting with 100 mL 5:1 hexanes/ethyl acetate followed by 400 mL 4:1 hexanes/ethyl acetate. This provided 0.36 g (50%) of the title compound.

[0549] TLC: (4:1 hexanes/ethyl acetate) Rf: 0.3. 1H NMR (400 MHz, CDCl3): δ 7.25 (m, 7H), 6.92 (t, 1H, J=7.5 Hz), 6.85 (d, 2H, J=8.1 Hz), 4.67 (d, 2H, J=6.0 Hz), 4.49 (t, 1H, J=9.6 Hz), 4.06 (m, 3H), 2.89 (m, 3H), 2.43 (m, 1H), 2.26 (m, 1H), 2.05 (m, 1H), 1.95 (m, 1H), 1.37 (s, 9H).

[0550] The product of Method H was converted to the title compound by procedures analogous to those of Methods A and B, from Example 1, except that quinoline-3-carboxylic acid is replaced with quinoxaline-2-carboxylic acid and methylamine is replaced with ammonia gas.

EXAMPLE 6

[0551] Quinoxaline-2-carboxylic Acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-cyclohexyl)-butyl]-amide and

[0552] Quinoxaline-2-carboxylic Acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-4-(1-hydroxy-cyclohexyl)-butyl]-amide

Method I

[0553] {1(S)-[4(S)-(1-Hydroxy-cyclohexyl)-5-oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic Acid Tert-Butyl Ester

[0554] To a solution of diisopropylamine (0.90 mL, 6.88 mmol) in THF (10 mL) at 0° C. was added a solution of n-butyl lithium (2.7 mL, 6.71 mmol, 2.5 M in hexanes). The solution was stirred for 15 minutes, then cooled to −78° C. To this was added dropwise a solution of {1(S)-[5-Oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester (1.0 g, 3.27 mmol prepared as in example 2, method C) in tetrahydrofuran (10 mL) and the reaction was stirred an additional 30 minutes. To this was added the appropriate ketone, e.g., cyclohexanone) (0.37 mL, 3.60 mmol), and the solution was warmed to ambient temperature. The reaction was quenched by addition of saturated aqueous bicarbonated NaHCO3) solution and the mixture extracted with diethyl ether. The combined organics were dried over magnesium sulfate (MgSO4), filtered and concentrated. Chromatography on silica gel gave a mixture of separable diastereomers of {[1(S)-[4(S)-(1-hydroxy-cyclohexyl)-5-oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester (0.687 g) and {f(S)-[4(R)-(1-hydroxy-cyclohexyl)-5-oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester (0.269 g) in 67% overall yield.

[0555] The products from Method I were converted to the title compounds by procedures analogous to those of Methods A and B, from Example 1, except that quinoline-3-carboxylic acid is replaced with quinoxaline-2-carboxylic acid and methylamine is replaced with ammonia gas.

EXAMPLE 7

[0556] Fluoro-quinoline-3-carboxylic Acid (1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-butyl)-amide and

[0557] Fluoro-quinoline-3-carboxylic Acid (1(S)-benzyl-4(R)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-butyl)-amide

Method J

[0558] {1(S)-[4(S)-(1-Hydroxy-cyclohexyl)-5-oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic Acid Tert-Butyl Ester

[0559] To a solution of the title compound from Method I, Example 5, (1.38 g, 3.42 mmol) in benzene (40 mL) was added (methoxycarbonylsulfamoyl)-triethylammonium hydroxide, inner salt (Burgess reagent) (1.30 g, 5.47 mmol) and the solution was warmed to reflux for 2 hours. The reaction was diluted with diethyl ether and washed with saturated aqueous brine. The organics were dried over magnesium sulfate, filtered and concentrated to give the crude elimination product. This was directly dissolved in 5:1 tetrahydrofuran/methanol (THF/MeOH)(30 mL) and transferred to a Parr flask containing 10% palladium on carbon (Pd/C) (1 g). The mixture was hydrogenated at 35 psi for 1.5 hours, then filtered through a pad of Celite and the filtrate concentrated. Chromatography on silica gel yielded the title compound as a mixture of separable diastereomers {1(S)-[4(S)-(1-hydroxy-cyclohexyl)-5-oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester (0.53 g) and {1(S)-[4(R)-(1-hydroxy-cyclohexyl)-5-oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester (0.29 g) in 62% overall yield.

[0560] The products from Method J were converted to the title compounds by procedures analogous to those of Methods A and B, from Example 1, except that quinoline-3-carboxylic acid is replaced with quinoxaline-2-carboxylic acid and methylamine is replaced with ammonia gas.

EXAMPLES 8-315

[0561] The compounds from Table 1 were prepared according to the methods described above, substituting where appropriate the correct R2 aldehyde, R3 group (such as allylic halide, alkyl triflate, ketone, etc.), R1 carboxylic acid or R4 and R5 amine where appropriate.

TABLE 1
EXAM-
PLE	NAME	M.P. (° C.)	LRMS
8.	Quinoxaline-2-carboxylic acid		455
	1(S)-cyclohexylmethyl-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-heptyl)-
	amide
9.	Quinoxaline-2-carboxylic acid
	(6-chloro-1-cyclohexylmethyl-2(S)-
	hydroxy-4(S)-methylcarbamoyl-hept-6-
	enyl)-amide
10.	Quinoline-3-carboxylic acid	155-157	414
	(2(S)-hydroxy-1(S)-isobutyl-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
11.	Quinoxaline-2-carboxylic acid	69-71	415
	1(S)-sec-butyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
12.	Quinoline-3-carboxylic acid		452
	1(S)-cyclohexylmethyl-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-hept-6-
	enyl)-amide
13.	Quinoxaline-2-carboxylic acid		453
	1(S)-cyclohexylmethyl-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-hept-6-
	enyl)-amide
14.	N-1(S)-Cyclohexylmethyl-2(S)-hydroxy-	115-119
	6-methyl-4(R)-methylcarbamoyl-
	heptyl)-5-phenyl-nicotinamide
15.	Quinoline-3-carboxylic acid 1(S)-	162-163
	benzyl-2(S)-hydroxy-6-methyl-4(R)-
	methylcarbamoyl-heptyl)-amide
16.	Quinoxaline-2-carboxylic acid		467
	1(S)-cyclohexylmethyl-4(R)-
	dimethylcarbamoyl-2(S)-hydroxy-6-
	methyl-hept-6-enyl)-amide
17.	Quinoline-3-carboxylic acid	171-175	453,
	1(S)-cyclohexylmethyl-2(S)-hydroxy-6-		436
	methyl-4(S)-methylcarbamoyl-heptyl)-
	amide
18.	Quinoxaline-2-carboxylic acid		455,
	1(S)-cyclohexylmethyl-2(S)-hydroxy-6-		437
	methyl-4(S)-methylcarbamoyl-heptyl)-
	amide
19.	Isoquinoline-4-carboxylic acid	180-182	454
	1(S)-cyclohexylmethyl-2(S)-hydroxy-6-
	methyl-4(S)-methylcarbamoyl-heptyl)-
	amide
20.	Quinoline-3-carboxylic acid	186-188	440,
	(4(R)-carbamoyl-1(S)-cyclohexylmethyl-		478,
	2(S)-hydroxy-6-methyl-heptyl)-amide		423
21.	Quinoline-3-carboxylic acid (5-	170.5-172.5	494
	cyclohexyl-1(S)-cyclohexylmethyl-2(S)-
	hydroxy-4(R)-methylcarbamoyl-pentyl)-
	amide
22.	Quinoline-3-carboxylic acid 1(S)-		454
	cyclohexylmethyl-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-heptyl)-
	amide
23.	Quinoline-3-carboxylic acid	200-201.5	454
	1(S)-cyclohexylmethyl-2(S)-hydroxy-6-
	methyl-4(S)-methylcarbamoyl-heptyl)-
	amide
24.	Quinoline-3-carboxylic acid	199-200.5	488
	1(S)-cyclohexylmethyl-2(S)-hydroxy-
	4(R)-methylcarbamoyl-5-phenyl-
	pentyl)-amide
25.	Quinoxaline-2-carboxylic acid	109-110.5	489
	1(S)-cyclohexylmethyl-2(S)-hydroxy-
	4(R)-methylcarbamoyl-5-phenyl-
	pentyl)-amide
26.	Quinoline-3-carboxylic acid	142-144	490,
	1(S)-benzyl-4(R)-butylcarbamoyl-2(S)-		417
	hydroxy-6-methyl-heptyl)-amide
27.	Quinoline-3-carboxylic acid	148-150	488,
	1(S)-benzyl-4(R)-cyclobutylcarbamoyl-		417
	2(S)-hydroxy-6-methyl-heptyl)-amide
28.	Quinoline-3-carboxylic acid	158-162	524,
	1(S)-benzyl-4(R)-benzylcarbamoyl-		417
	2(S)-hydroxy-6-methyl-heptyl)-amide
29.	Quinoline-3-carboxylic acid	174-179	474
	1(S)-benzyl-4(R)-
	cyclopropylcarbamoyl-2(S)-hydroxy-6-
	methyl-heptyl)-amide
30.	Quinoline-3-carboxylic acid	190-192.5	448
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(S)-methylcarbamoyl-heptyl)-amide
31.	Quinoline-3-carboxylic acid	175-176	462
	1(S)-benzyl-4(R)-ethylcarbamoyl-2(S)-
	hydroxy-6-methyl-heptyl)-amide
32.	Quinoline-3-carboxylic acid		476
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-propylcarbamoyl-heptyl)-amide
33.	Quinoline-3-carboxylic acid	158-162	478
	[1-benzyl-2(S)-hydroxy-4(R)-(2-
	hydroxy-ethylcarbamoyl)-6-methyl-
	heptyl]-amide
34.	Cinnoline-4(R)-carboxylic acid	185-186.5	449
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
35.	Isoquinoline-4-carboxylic acid	200-201	448
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
36.	Quinoxaline-2-carboxylic acid	166-167	449
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
37.	N-1(S)-Benzyl-2(S)-hydroxy-6-methyl-	184.5-185.5	478
	4(R)-methylcarbamoyl-heptyl)-5-
	bromo-nicotinamide
38.	Quinoline-3-carboxylic acid		454
	1(R)-cyclohexylmethyl-2(R)-hydroxy-6-
	methyl-4(S)-methylcarbamoyl-heptyl)-
	amide
39.	Quinoxaline-2-carboxylic acid	196-197	554
	[1(S)-(4-benzyloxy-benzyl)-2(S)-
	hydroxy-6-methyl-4(R)-
	methylcarbamoyl-heptyl]-amide,
40.	Quinoline-3-carboxylic acid	178-179	555
	[1(S)-(4-benzyloxy-benzyl)-2(S)-
	hydroxy-6-methyl-4(R)-
	methylcarbamoyl-heptyl]-amide
41.	Isoquinoline-1-carboxylic acid	178-179	448
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
42.	Quinoline-4-carboxylic acid	189-192	448
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
43.	Quinoline-6-carboxylic acid	165-167	448
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
44.	Quinoline-3-carboxylic acid	220.5-222.5	464
	[2(S)-hydroxy-1(S)-(4-hydroxy-benzyl)-
	6-methyl-4(R)-methylcarbamoyl-
	heptyl]-amide
45.	Quinoline-2-carboxylic acid	160-161.5	449
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
46.	Naphthalene-2-carboxylic acid	218-220	447
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
47.	Quinoline-3-carboxylic acid	172-174	486
	1(S)-benzyl-5-cyclohex-1-enyl-2(S)-
	hydroxy-4(R)-methylcarbamoyl-pentyl)-
	amide
48.	Quinoline-3-carboxylic acid	153-154	504
	[1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-(3-methyl-butylcarbamoyl)-heptyl]-
	amide
49.	Quinoxaline-2-carboxylic acid	157-163	449
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(S)-methylcarbamoyl-heptyl)-amide
50.	Trifluoro-methanesulfonic acid	168-170	596
	4-{3(S)-hydroxy-7-methyl-5(R)-
	methylcarbamoyl-2(S)-[(quinoline-3-
	carbonyl)-amino]-octyl}-
	phenyl ester
51.	Trifluoro-methanesulfonic acid		597
	4-{3(S)-hydroxy-7-methyl-5(R)-
	methylcarbamoyl-2(S)-[(quinoxaline-
	2-carbonyl)-amino]-octyl}-phenyl ester
52.	Quinoline-3-carboxylic acid	185-187	488
	1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-
	4(R)-methylcarbamoyl-pentyl)-amide
53.	Quinoxaline-2-carboxylic acid	132-134	489,
	1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-		471
	4(R)-methylcarbamoyl-pentyl)-amide
54.	Isoquinoline-3-carboxylic acid	150.5-151.5	488
	1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-
	4(R)-methylcarbamoyl-pentyl)-amide
55.	N-1(S)-Benzyl-5-cyclohexyl-2(S)-	199-200.5	518
	hydroxy-4(R)-methylcarbamoyl-pentyl)-
	5-bromo-nicotinamide
56.	Quinoline-3-carboxylic acid 1(S)-		472
	benzyl-2(S)-hydroxy-6-methyl-4(R)-
	prop-2-ynylcarbamoyl-heptyl)-amide
57.	Quinoline-3-carboxylic acid		456,
	1(S)-cyclohexylmethyl-2(S)-hydroxy-		438,
	4(R)-hydroxycarbamoyl-6-methyl-		423
	heptyl)-amide
58.	Quinoline-3-carboxylic acid 2(S)-	176-177	478
	hydroxy-1(S)-(4-methoxy-benzyl)-6-
	methyl-4(R)-methylcarbamoyl-heptyl]-
	amide
59.	Isoquinoline-3-carboxylic acid (5-	205-207	494
	cyclohexyl-1(S)-cyclohexylmethyl-2(S)-
	hydroxy-4(R)-methylcarbamoyl-pentyl)-
	amide,
60.	5-Bromo-N-(5-cyclohexyl-1(S)-	173.5-175	444
	cyclohexylmethyl-2(S)-hydroxy-4(R)-
	methylcarbamoyl-pentyl)-nicotinamide
61.	Quinoxaline-2-carboxylic acid		479
	[2(S)-hydroxy-1(S)-(4-methoxy-benzyl)-
	6-methyl-4(R)-methylcarbamoyl-
	heptyl]-amide
62.	Isoquinoline-4-carboxylic acid	220.5-224	494
	(5-cyclohexyl-1(S)-cyclohexylmethyl-
	2(S)-hydroxy-4(R)-methylcarbamoyl-
	pentyl)-amide
63.	Quinoline-2-carboxylic acid	120-122	488
	1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-
	4(R)-methylcarbamoyl-pentyl)-amide
64.	lsoquinoline-4-carboxylic acid	177-180	488
	1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-
	4(R)-methylcarbamoyl-pentyl)-amide,
65.	Quinoxaline-2-carboxylic acid	170-172	465
	[2(S)-hydroxy-1(S)-(4-hydroxy-benzyl)-
	6-methyl-4(R)-methylcarbamoyl-
	heptyl]-amide,
66.	Quinoxaline-2-carboxylic acid		496
	(5-cyclohexyl-1(S)-cyclohexylmethyl-
	2(S)-hydroxy-4(R)-methylcarbamoyl-
	pentyl)-amide
67.	Quinoline-3-carboxylic acid	212.5-213.5	482
	[1(S)-(4-chloro-benzyl)-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-heptyl]-
	amide
68.	Quinoxaline-2-carboxylic acid		483
	[1(S)-(4-chloro-benzyl)-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-heptyl]-
	amide
69.	Quinoline-3-carboxylic acid	173.5-175	468,
	1(S)-cyclohexylmethyl-2(S)-hydroxy-7-		450
	methyl-4(R)-methylcarbamoyl-octyl)-
	amide
70.	Quinoxaline-2-carboxylic acid	78-80	470
	1(S)-cyclohexylmethyl-2(S)-hydroxy-7-
	methyl-4(R)-methylcarbamoyl-octyl)-
	amide
71.	Quinoline-3-carboxylic acid	198-201	522
	[1(S)-(4-chloro-benzyl)-5-cyclohexyl-
	2(S)-hydroxy-4(R)-methylcarbamoyl-
	pentyl]-amide
72.	Quinoxaline-2-carboxylic acid		523
	[1(S)-(4-chloro-benzyl)-5-cyclohexyl-
	2(S)-hydroxy-4(R)-methylcarbamoyl-
	pentyl]-amide
73.	Quinoline-2-carboxylic acid		522
	[1(S)-(4-chloro-benzyl)-5-cyclohexyl-
	2(S)-hydroxy-4(R)-methylcarbamoyl-
	pentyl]-amide
74.	Benzofuran-2-carboxylic acid	181-183	437
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
75.	N-1(S)-Benzyl-2(S)-hydroxy-6-methyl-	195-196	466,
	4(R)-methylcarbamoyl-heptyl)-5,6-		432
	dichloro-nicotinamide
76.	Quinoline-3-carboxylic acid	188-190	462
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-methylcarbamoyl-octyl)-amide
77.	N-1(S)-Benzyl-2(S)-hydroxy-7-methyl-	188-189	490
	4(R)-methylcarbamoyl-octyl)-5-bromo-
	nicotinamide
78.	5,6,7,8-Tetrahydro-quinoline-3-	142.5-144.5	452
	carboxylic acid
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
79.	Quinoxaline-2-carboxylic acid	147-149	463
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-methylcarbamoyl-octyl)-amide
80.	Quinoline-2-carboxylic acid	156-158	462
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-methylcarbamoyl-octyl)-amide,
81.	lsoquinoline-4-carboxylic acid	199-202	462
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-methylcarbamoyl-octyl)-amide
82.	Quinoxaline-2-carboxylic acid		517,
	[1(S)-(3,4-dichloro-benzyl)-2(S)-		483
	hydroxy-6-methyl-4(R)-
	methylcarbamoyl-heptyl]-amide
83.	Benzo[b]thiophene-2-carboxylic acid	179-181	453
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
84.	2-Methyl-quinoline-3-carboxylic acid	225-226.5	462
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
85.	6,7-Dimethoxy-quinoline-3-carboxylic	211-214	508
	acid
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
86.	6,7-Difluoro-quinoline-3-carboxylic acid	187-189	484,
	1(S)-benzyl-2(S)-hydroxy-6-methyl-		466
	4(R)-methylcarbamoyl-heptyl)-amide
87.	1H-Benzoimidazole-2-carboxylic acid	136-140	437
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
88.	5-Methyl-pyrazine-2-carboxylic acid	171.5-172.5	413
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
89.	Quinoline-3-carboxylic acid	184-186	466
	[1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-heptyl]-
	amide
90.	Quinoxaline-2-carboxylic acid	153-156	467
	[1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-heptyl]-
	amide
91.	5-Chloro-1H-indole-2-carboxylic acid	245-247	470
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
92.	Quinoxaline-2-carboxylic acid	194-194.5	449,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		432
	hydroxy-7-methyl-octyl)-amide
93.	2-Methoxy-quinoline-3-carboxylic acid	175-181	478
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide,
94.	5,6-Dichloro-1H-benzoimidazole-2-	114-117	505
	carboxylic acid 1(S)-benzyl-2(S)-
	hydroxy-6-methyl-4(R)-
	methylcarbamoyl-heptyl)-amide
95.	Benzothiazole-2-carboxylic acid	86-89	454
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
96.	7,8-Difluoro-quinoline-3-carboxylic acid	179-182	484
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
97.	6,7,8-Trifluoro-quinoline-3-carboxylic	156-161	502,
	acid		484
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
98.	5,8-Dimethyl-quinoline-3-carboxylic	197-199	476
	acid 1(S)-benzyl-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-heptyl)-
	amide
99.	Quinoxaline-2-carboxylic acid	103-106	505
	1(S)-benzyl-4(R)-butylcarbamoyl-2(S)-
	hydroxy-7-methyl-octyl)-amide
100.	Quinoline-3-carboxylic acid		516
	[1(S)-(3,4-dichloro-benzyl)-2(S)-
	hydroxy-6-methyl-4(R)-
	methylcarbamoyl-heptyl]-amide
101.	5,6,7,8-Tetrahydro-quinoline-3-	169.5-172.5	466
	carboxylic acid
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-methylcarbamoyl-octyl)-amide
102.	Quinoline-3-carboxylic acid	176-178	474
	1(S)-benzyl-5-cyclopentyl-2(S)-
	hydroxy-4(R)-methylcarbamoyl-pentyl)-
	amide
103.	Quinoxaline-2-carboxylic acid	120-122	475
	1(S)-benzyl-5-cyclopentyl-2(S)-
	hydroxy-4(R)-methylcarbamoyl-pentyl)-
	amide
104.	N-1(S)-Benzyl-5-cyclopentyl-2(S)-	194-198	504
	hydroxy-4(R)-methylcarbamoyl-pentyl)-
	5-bromo-nicotinamide
105.	5,6,7,8-Tetrahydro-quinoline-3-	143-146	478
	carboxylic acid 1(S)-benzyl-5-
	cyclopentyl-2(S)-hydroxy-4(R)-
	methylcarbamoyl-pentyl)-amide,
106.	Quinoxaline-2-carboxylic acid	217-219	461,
	1(S)-benzyl-4(R)-carbamoyl-5-		444
	cyclopentyl-2(S)-hydroxy-pentyl)-amide
107.	6,7-Dihydro-5H-[1]pyrindine-3-	154.5-156	452,
	carboxylic acid		349
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-methylcarbamoyl-octyl)-amide
108.	Quinoxaline-2-carboxylic acid	95-98	491,
	[1(S)-(4,4-difluoro-cyclohexylmethyl)-		473
	2(S)-hydroxy-6-methyl-4(R)-
	methylcarbamoyl-heptyl]-amide
109.	Quinoxaline-2-carboxylic acid	95-98	506,
	[1(S)-(4,4-difluoro-cyclohexylmethyl)-		488
	2(S)-hydroxy-7-methyl-4(R)-
	methylcarbamoyl-octyl]-amide
110.	Quinoxaline-2-carboxylic acid	129-133	478
	1(S)-benzyl-4(R)-ethylcarbamoyl-2(S)-
	hydroxy-7-methyl-octyl)-amide
111.	Quinoxaline-2-carboxylic acid	125-130	492
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-propylcarbamoyl-octyl)-amide
112.	Quinoxaline-2-carboxylic acid	168-169	490,
	1(S)-benzyl-4(R)-		472
	cyclopropylcarbamoyl-2(S)-hydroxy-7-
	methyl-octyl)-amide
113.	Quinoxaline-2-carboxylic acid	148-150	504,
	1(S)-benzyl-4(R)-cyclobutylcarbamoyl-		486
	2(S)-hydroxy-7-methyl-octyl)-amide
114.	Quinoxaline-2-carboxylic acid	151-154	530
	[1(S)-(4-difluoromethoxy-benzyl)-2(S)-
	hydroxy-7-methyl-4(R)-
	methylcarbamoyl-octyl]-amide
115.	4-{3(S)-Hydroxy-7-methyl-5(R)-	87-95	508
	methylcarbamoyl-2(S)-[(quinoxaline-
	2-carbonyl)-amino]-octyl}-benzoic acid
	methyl ester
116.	Quinoxaline-2-carboxylic acid 1(S)-		379
	benzyl-4-carbamoyl-2(S)-hydroxy-
	butyl)-amide
117.	6,7,8-Trifluoro-quinoline-3-carboxylic	206-207	516,
	acid		498
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-methylcarbamoyl-octyl)-amide
118.	6,7,8-Trifluoro-quinoline-3-carboxylic	205-206	502,
	acid		485
	1(S)-benzyl-4(R)-carbamoyl-2(S)-
	hydroxy-7-methyl-octyl)-amide
119.	6,8-Difluoro-quinoline-3-carboxylic acid	198-200	498
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-methylcarbamoyl-octyl)-amide
120.	6,8-Difluoro-quinoline-3-carboxylic acid	188-190	484,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		467
	hydroxy-7-methyl-octyl)-amide
121.	Quinoxaline-2-carboxylic acid	102-104	517,
	1(S)-benzyl-4(R)-butylcarbamoyl-5-		499
	cyclopentyl-2(S)-hydroxy-pentyl)-amide
122.	6-Methyl-pyridine-2-carboxylic acid	74-76
	1(S)-benzyl-2(S)-hydroxy-6-methyl-
	4(R)-methylcarbamoyl-heptyl)-amide
123.	Quinoxaline-2-carboxylic acid	145.5-146.5	477
	1(S)-benzyl-2(S)-hydroxy-8-methyl-
	4(R)-methylcarbamoyl-nonyl)-amide
124.	Quinoxaline-2-carboxylic acid	163-165	463
	1(S)-benzyl-4(R)-carbamoyl-2(S)-
	hydroxy-8-methyl-nonyl)-amide
125.	Quinoxaline-2-carboxylic acid	123-125	539,
	1(S)-biphenyl-4-ylmethyl-2(S)-hydroxy-		521,
	7-methyl-4(R)-methylcarbamoyl-octyl)-		508
	amide
126.	Quinoxaline-2-carboxylic acid	168-170	447,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		430
	hydroxy-7-methyl-oct-6-enyl)-amide
127.	Quinoxaline-2-carboxylic acid	121-123
	(2(S)-hydroxy-6-methyl-4(R)-
	methylcarbamoyl-1(S)-naphthalen-2-
	ylmethyl-heptyl)-amide
128.	Quinoxaline-2-carboxylic acid	77-79	463,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		446
	hydroxy-7,7-dimethyl-octyl)-amide
129.	Quinoxaline-2-carboxylic acid	195-199	477,
	1(S)-benzyl-2(S)-hydroxy-7,7-dimethyl-		459
	4(R)-methylcarbamoyl-octyl)-amide
130.	Quinoxaline-2-carboxylic acid	168-172	469,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		452
	hydroxy-5-phenyl-pentyl)-amide
131.	Quinoxaline-2-carboxylic acid	205-206	508
	1(S)-biphenyl-4-ylmethyl-4(R)-
	carbamoyl-2(S)-hydroxy-7-methyl-
	octyl)-amide
132.	Quinoxaline-2-carboxylic acid	170-172	525,
	[1(S)-benzyl-5-(4,4-difluoro-		507
	cyclohexyl)-2(S)-hydroxy-4(R)-
	methylcarbamoyl-pentyl]-amide
133.	Quinoxaline-2-carboxylic acid	174-176	511,
	[1(S)-benzyl-4(R)-carbamoyl-5-(4,4-		493
	difluoro-cyclohexyl)-2(S)-hydroxy-
	pentyl]-amide
134.	Quinoxaline-2-carboxylic acid	158.5-159.5	481,
	[1(S)-(3-fluoro-benzyl)-2(S)-hydroxy-7-		463
	methyl-4(R)-methylcarbamoyl-octyl]-
	amide
135.	Quinoxaline-2-carboxylic acid	191-191.5	467,
	[4(R)-carbamoyl-1(S)-(3-fluoro-benzyl)-		449
	2(S)-hydroxy-7-methyl-octyl]-amide
136.	Quinoxaline-2-carboxylic acid	65-68	461,
	1(S)-benzyl-2(S)-hydroxy-7-methyl-		443
	4(R)-methylcarbamoyl-oct-6-enyl)-
	amide
137.	6,7,8-Trifluoro-quinoline-3-carboxylic	158-161	541,
	acid 1(S)-benzyl-2(S)-hydroxy-7(S)-		523
	methyl-4(R)-methylcarbamoyl-nonyl)-
	amide
138.	Quinoxaline-2-carboxylic acid	185-187	446
	1(S)-benzyl-4(R)-carbamoyl-2(S)-
	hydroxy-7(S)-methyl-nonyl)-amide
139.	Quinoxaline-2-carboxylic acid	148-150	482,
	1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-		463
	methyl-4(R)-methylcarbamoyl-octyl)-
	amide
140.	Quinoxaline-2-carboxylic acid	184-186	467,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		449
	2(S)-hydroxy-7-methyl-octyl)-amide
141.	Quinoxaline-2-carboxylic acid	137-139.5	478
	1(S)-benzyl-2(S)-hydroxy-7-methyl-
	4(R)-methylcarbamoyl-nonyl)-amide
142.	Quinoxaline-2-carboxylic acid	68-70
	1(S)-benzyl-4(R)-dimethylcarbamoyl-
	2(S)-hydroxy-7-methyl-octyl)-amide
143.	7,8-Difluoro-quinoline-3-carboxylic acid	175	518,
	1(S)-benzyl-2(S)-hydroxy-4(R)-	(Dec.)	500
	methylcarbamoyl-5-phenyl-pentyl)-
	amide
144.	7,8-Difluoro-quinoline-3-carboxylic acid	198-201	498,
	1(S)-benzyl-2(S)-hydroxy-7-methyl-		480
	4(R)-methylcarbamoyl-octyl)-amide
145.	8-Fluoro-quinoline-3-carboxylic acid	179-183	480,
	1(S)-benzyl-2(S)-hydroxy-7-methyl-		462
	4(R)-methylcarbamoyl-octyl)-amide
146.	Quinoxaline-2-carboxylic acid	130-132	462,
	1(S)-benzyl-2(S)-hydroxy-4(R)-		448
	methylcarbamoyl-non-6-enyl)-amide
147.	Quinoxaline-2-carboxylic acid	154-155	448,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		430
	hydroxy-non-6-enyl)-amide
148.	7,8-Difluoro-quinoline-3-carboxylic acid	188-190	485,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		467
	hydroxy-7-methyl-octyl)-amide
149.	8-Fluoro-quinoline-3-carboxylic acid	192-196	466,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		449
	hydroxy-7-methyl-octyl)-amide
150.	Quinoxaline-2-carboxylic acid	188.5-189.5	450
	1(S)-benzyl-4(R)-carbamoyl-2(S)-
	hydroxy-nonyl)-amide
151.	2(S)-{2(S)-hydroxy-4-phenyl-3(S)-	178-180
	[(quinoxaline-2-carbonyl)-amino]-butyl}-
	N1,N4-dimethyl-succinamide
152.	Quinoxaline-2-carboxylic acid	105-108	496
	1(S)-benzyl-4(R)-ethylcarbamoyl-7-
	fluoro-2(S)-hydroxy-7-methyl-octyl)-
	amide
153.	Quinoxaline-2-carboxylic acid	110-112	523,
	1(S)-benzyl-4(R)-butylcarbamoyl-7-		505
	fluoro-2(S)-hydroxy-7-methyl-octyl)-
	amide
154.	Quinoxaline-2-carboxylic acid	145-147	499
	[7-fluoro-1(S)-(4-fluoro-benzyl)-2(S)-
	hydroxy-7-methyl-4(R)-
	methylcarbamoyl-octyl]-amide
155.	Quinoxaline-2-carboxylic acid	206-207	536,
	[4(R)-carbamoyl-1(S)-(3,4-dichloro-		518
	benzyl)-7-fluoro-2(S)-hydroxy-7-methyl-
	octyl]-amide
156.	7,8-Difluoro-quinoline-3-carboxylic acid	187-189	571
	[4(R)-carbamoyl-1(S)-(3,4-dichloro-
	benzyl)-7-fluoro-2(S)-hydroxy-7-methyl-
	octyl]-amide
157.	Quinoxaline-2-carboxylic acid	223-225	478
	(4(R)-carbamoyl-2(S)-hydroxy-7-
	methyl-1(S)-phenethyl-octyl)-amide,
158.	7,8-Difluoro-quinoline-3-carboxylic acid	208-210	463,
	[4(R)-carbamoyl-7-fluoro-1(S)-(4-		445
	fluoro-benzyl)-2(S)-hydroxy-7-methyl-
	octyl]-amide
159.	Quinoxaline-2-carboxylic acid		520
	[4(R)-carbamoyl-7-fluoro-1(S)-(4-
	fluoro-benzyl)-2(S)-hydroxy-7-methyl-
	octyl]-amide
160.	Quinoxaline-2-carboxylic acid		551
	[1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-
	methyl-4(R)-(4-methyl-piperazine-1-
	carbonyl)-octyl]-amide,
161.	Quinoxaline-2-carboxylic acid	212-214	477,
	[1(S)-benzyl-4(R)-carbamoyl-2(S)-		459
	hydroxy-5-(tetrahydro-pyran-4(R)-yl)-
	pentyl]-amide
162.	Quinoxaline-2-carboxylic acid		536
	[1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-
	methyl-4(R)-(piperidine-1-carbonyl)-
	octyl]-amide
163.	Quinoxaline-2-carboxylic acid		537
	[1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-
	methyl-4(R)-(morpholine-4-carbonyl)-
	octyl]-amide,
164.	Quinoxaline-2-carboxylic acid	90-100	481,
	[1(S)-benzyl-3-(2-carbamoyl-indan-2-		464
	yl)-2(S)-hydroxy-propyl]-amide
165.	Quinoxaline-2-carboxylic acid	212-216
	1(S)-benzyl-2(S)-hydroxy-4(R)-	(Dec.)
	methylcarbamoyl-7-phenyl-hept-6-
	enyl)-amide
166.	Quinoline-2-carboxylic acid	163.5-165	466,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		449
	2(S)-hydroxy-7-methyl-octyl)-amide
167.	6,7-Dihydro-5H-[1]pyrindine-3-	175-178	456
	carboxylic acid
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-
	2(S)-hydroxy-7-methyl-octyl)-amide
168.	Quinoxaline-2-carboxylic acid (1(S)-	222-223	461,
	benzyl-4-carbamoyl-4(S)-cyclohexyl-		444
	2(S)-hydroxy-butyl)-amide;
169.	Quinoxaline-2-carboxylic acid (1(S)-	178-180	461,
	benzyl-4-carbamoyl-4(S)-cyclohexyl-		444
	2(S)-hydroxy-butyl)-amide
170.	Quinoxaline-2-carboxylic acid (1(S)-	229-232	447
	benzyl-4-carbamoyl-4(S)-cyclohexyl-
	2(S)-hydroxy-butyl)-amide
171.	Quinoxaline-2-carboxylic acid (1(S)-	126-128	447
	benzyl-4-carbamoyl-4(S)-cyclopentyl-
	2(S)-hydroxy-butyl)-amide;
172.	Quinoline-3-carboxylic acid	200-202	466,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		449
	2(S)-hydroxy-7-methyl-octyl)-amide
173.	N-1(S)-Benzyl-4(R)-carbamoyl-7-	181-183	476
	fluoro-2(S)-hydroxy-7-methyl-octyl)-5-
	bromo-nicotinamide
174.	Quinoxaline-2-carboxylic acid	184-187	466,
	[4(R)-carbamoyl-1-(2(S)-fluoro-benzyl)-		448
	2(S)-hydroxy-7-methyl-octyl]-amide
175.	Quinoxaline-2-carboxylic acid	213-215	466
	[4(R)-carbamoyl-1(S)-(2-fluoro-benzyl)-
	2(S)-hydroxy-7-methyl-octyl]-amide
176.	Quinoxaline-2-carboxylic acid [1(S)-		502
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(4-isopropyl-cyclohexyl)-butyl]-amide;
177.	Quinoxaline-2-carboxylic acid		454,
	(4(R)-carbamoyl-2(S)-hydroxy-7-		436
	methyl-1(S)-thiophen-2-ylmethyl-octyl)-
	amide
178.	Quinoxaline-2-carboxylic acid	195-196	456
	(4(R)-carbamoyl-2(S)-hydroxy-7-
	methyl-1(S)-thiazol-4-ylmethyl-octyl)-
	amide
179.	Quinoxaline-2-carboxylic acid [1(S)-	188-190	516
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(3,3,5,5-tetramethyl-cyclohexyl)-butyl]-
	amide
180.	Quinoxaline-2-carboxylic acid (1(S)-		495
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	indan-2-yl-butyl)-amide;
181.	Quinoxaline-2-carboxylic acid (1(S)-	216-217	474,
	benzyl-4(S)-carbamoyl-4-cycloheptyl-		457
	2(S)-hydroxy-butyl)-amide;
182.	Quinoxaline-2-carboxylic acid (1(S)-		477
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-5-
	propyl-octyl)-amide;
183.	Quinoxaline-2-carboxylic acid (1(S)-
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-5-
	propyl-oct-5-enyl)-amide;
184.	Quinoxaline-2-carboxylic acid
	1(S)-benzyl-4(R)-carbamoyl-2(S),7-
	dihydroxy-7-methyl-octyl)-amide
185.	Quinoxaline-2-carboxylic acid		467,
	1(S)-benzyl-7-chloro-2(S)-hydroxy-		449
	4(R)-methylcarbamoyl-hept-6-enyl)-
	amide
186.	Quinoxaline-2-carboxylic acid		467,
	1(S)-benzyl-7-chloro-2(S)-hydroxy-		449
	4(R)-methylcarbamoyl-hept-6-enyl)-
	amide
187.	Quinoxaline-2-carboxylic acid	160-162	467,
	1(S)-benzyl-6-chloro-2(S)-hydroxy-		449
	4(S)-methylcarbamoyl-hept-6-enyl)-
	amide
188.	Quinoxaline-2-carboxylic acid	203-204.5
	1(S)-benzyl-4(R)-carbamoyl-6-chloro-
	2(S)-hydroxy-hept-6-enyl)-amide
189.	Quinoxaline-2-carboxylic acid	171-174	447,
	1(S)-benzyl-4(S)-carbamoyl-6-		429
	cyclopropyl-2(S)-hydroxy-hexyl)-amide
190.	Quinoxaline-2-carboxylic acid	146-148	461,
	1(S)-benzyl-6-cyclopropyl-2(S)-		443
	hydroxy-4(R)-methylcarbamoyl-hexyl)-
	amide
191.	Quinoxaline-2-carboxylic acid [1(S)-	218-220	475,
	benzyl-4(R)-carbamoyl-2(S)-hydroxy-		457
	4(S)-(4-methyl-cyclohexyl)-butyl]-
	amide;
192.	Quinoxaline-2-carboxylic acid (1(S)-	190-191	495,
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-		477
	indan-2-yl-butyl)-amide;
193.	Quinoxaline-2-carboxylic acid	184-187	553,
	[1(S)-benzyl-4(R)-carbamoyl-2(S)-		536
	hydroxy-5-(4-trifluoromethoxy-phenyl)-
	pentyl]-amide
194.	Quinoxaline-2-carboxylic acid	164-166	487,
	[1(S)-benzyl-4(R)-carbamoyl-5-(4-		470
	fluoro-phenyl)-2(S)-hydroxy-pentyl]-
	amide
195.	Quinoxaline-2-carboxylic acid	165-166	436
	1(S)-benzyl-4(R)-carbamoyl-7-chloro-
	2(S)-hydroxy-hept-6-enyl)-amide
196.	Quinoxaline-2-carboxylic acid	158-160	436
	1(S)-benzyl-4(R)-carbamoyl-7-chloro-
	2(S)-hydroxy-hept-6-enyl)-amide
197.	3-Hydroxy-quinoxaline-2-carboxylic	185-189	483,
	acid 1(S)-benzyl-4(R)-carbamoyl-7-		465
	fluoro-2(S)-hydroxy-7-methyl-octyl)-
	amide
198.	Quinoxaline-2-carboxylic acid	183-184
	1(S)-benzyl-4(R)-benzylcarbamoyl-7-
	fluoro-2(S)-hydroxy-7-methyl-octyl)-
	amide
199.	Quinoxaline-2-carboxylic acid	188-191
	{1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-
	methyl-4(R)-[(pyridin-3-ylmethyl)-
	carbamoyl]-octyl}-amide
200.	Quinoxaline-2-carboxylic acid		571,
	1(S)-benzyl-8,8-trifluoro-2(S)-hydroxy-		553
	4(R)-methylcarbamoyl-7-
	trifluoromethyl-octyl)-amide
201.	Quinoxaline-2-carboxylic acid	187-193	553
	1(S)-benzyl-4(R)-carbamoyl-8,8-
	trifluoro-2(S)-hydroxy-7-trifluoromethyl-
	octyl)-amide
202.	Quinoxaline-2-carboxylic acid	170-173	502
	[2(S)-hydroxy-7-methyl-4(R)-
	methylcarbamoyl-1(S)-(4-
	methylcarbamoyl-benzyl)-octyl]-amide
203.	Quinoxaline-2-carboxylic acid (1(S)-	215-218	448,
	benzyl-4(S)-carbamoyl-5-ethyl-2(S)-		431
	hydroxy-heptyl)-amide;
204.	Quinoxaline-2-carboxylic acid [1(S)-	151-154
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(tetrahydro-pyran-4-yl)-butyl]-amide;
205.	Quinoxaline-2-carboxylic acid	155-156	572
	[1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-
	methyl-4(R)-(2-pyridin-2-yl-
	ethylcarbamoyl)-octyl]-amide
206.	Quinoxaline-2-carboxylic acid	162-164	617
	[1(S)-benzyl-4(R)-(3,4-dimethoxy-
	benzylcarbamoyl)-7-fluoro-2(S)-
	hydroxy-7-methyl-octyl]-amide
207.	Quinoxaline-2-carboxylic acid 1(S)-		420
	benzyl-4(R)-carbamoyl-2(S)-hydroxy-6-
	methoxy-hexyl)-amide
208.	Quinoxaline-2-carboxylic acid	172-175	450
	1(S)-benzyl-4(R)-carbamoyl-7-chloro-
	2(S)-hydroxy-oct-6-enyl)-amide
209.	Quinoxaline-2-carboxylic acid	108-111	463
	1(S)-benzyl-7-chloro-2(S)-hydroxy-
	4(R)-methylcarbamoyl-oct-6-enyl)-
	amide
210.	Quinoxaline-2-carboxylic acid [1(S)-	221-222	489,
	benzyl-4(R)-carbamoyl-4-(3,5-dimethyl-		471
	cyclohexyl)-2(S)-hydroxy-butyl]-amide;
211.	Quinoxaline-2-carboxylic acid {1(S)-	138-140	557,
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-		540
	4(R)-[(pyridin-2-ylmethyl)-carbamoyl]-
	octyl}-amide
212.	Quinoxaline-2-carboxylic acid {1(S)-	138-140	587,
	benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2-		569
	(4-hydroxy-phenyl)-ethylcarbamoyl]-7-
	methyl-octyl}-amide
213.	Quinoxaline-2-carboxylic acid {1(S)-	174-175	563,
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-		545
	4(R)-[(thiophen-2-ylmethyl)-
	carbamoyl]-octyl}-amide
214.	Quinoxaline-2-carboxylic acid	194.5-196.5	482
	1(S)-benzyl-4(R)-carbamoyl-2(S)-
	hydroxy-6-phenoxy-hexyl)-amide
215.	Quinoxaline-2-carboxylic acid	113-118	448
	1(S)-benzyl-4(R)-carbamoyl-2(S)-	(Mix)
	hydroxy-6-isopropoxy-hexyl)-amide
216.	Quinoxaline-2-carboxylic acid {1(S)-	207-210	650
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-
	4(R)-[2-(4-sulfamoyl-phenyl)-
	ethylcarbamoyl]-octyl}-amide
217.	Quinoxaline-2-carboxylic acid {1(S)-	100-104	558
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-
	4(R)-[(pyridin-4-ylmethyl)-carbamoyl]-
	octyl}-amide
218.	Quinoxaline-2-carboxylic acid [1(S)-	78-79	555,
	benzyl-4(R)-(2-ethylsulfanyl-		537
	ethylcarbamoyl)-7-fluoro-2(S)-hydroxy-
	7-methyl-octyl]-amide
219.	Quinoxaline-2-carboxylic acid [1(S)-	48-50	507
	benzyl-7-fluoro-2(S)-hydroxy-4(R)-(2-
	methoxy-ethylcarbamoyl)-7-methyl-
	octyl]-amide
220.	Quinoxaline-2-carboxylic acid [1(S)-	154-155	572
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-
	4(R)-(2-pyridin-3-yl-ethylcarbamoyl)-
	octyl]-amide
221.	Quinoxaline-2-carboxylic acid [1(S)-	78-80	572
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-
	4(R)-(2-pyridin-4-yl-ethylcarbamoyl)-
	octyl]-amide
222.	Quinoxaline-6-carboxylic acid	190-192	467
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-
	2(S)-hydroxy-7-methyl-octyl)-amide
223.	Quinoxaline-2-carboxylic acid	184-189	479,
	1(S)-benzyl-6-tert-butoxy-4(R)-		461
	carbamoyl-2(S)-hydroxy-hexyl)-amide
224.	Quinoxaline-2-carboxylic acid {1(S)-	100-105	574
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-
	4(R)-[2-1-methyl-1H-pyrrol-2-yl)-
	ethylcarbamoyl]-octyl}-amide
225.	Quinoxaline-2-carboxylic acid [1(S)-	140-150	511,
	benzyl-4(S)-carbamoyl-4-(1,1-dioxo-		494
	thiopyran-4-yl)-2(S)-hydroxy-butyl]-
	amide;
226.	Quinoxaline-2-carboxylic acid {1(S)-		640,
	benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2-		622
	(6-methoxy-1H-indol-3-yl)-
	ethylcarbamoyl]-7-methyl-octyl}-amide,
227.	Quinoxaline-2-carboxylic acid	135	587,
	[1(S)-benzyl-7-fluoro-2(S)-hydroxy-		569
	4(R)-(2-methoxy-benzylcarbamoyl)-7-
	methyl-octyl]-amide
228.	Quinoxaline-2-carboxylic acid		587,
	[1(S)-benzyl-7-fluoro-2(S)-hydroxy-		569
	4(R)-(3-methoxy-benzylcarbamoyl)-7-
	methyl-octyl]-amide
229.	Quinoxaline-2-carboxylic acid [1(S)-	152-154	577
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-
	4(R)-(2-thiophen-2-yl-ethylcarbamoyl)-
	octyl]-amide
230.	Quinoxaline-2-carboxylic acid {1(S)-	107-108	610
	benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2-
	(1H-indol-3-yl)-ethylcarbamoyl]-7-
	methyl-octyl}-amide
231.	Quinoxaline-2-carboxylic acid {4(R)-[2-		586
	(4-amino-phenyl)-ethylcarbamoyl]-1(S)-
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-
	octyl}-amide
232.	Quinoxaline-2-carboxylic acid {1(S)-	109-112	631,
	benzyl-4(R)-[2-(3,5-dimethoxy-phenyl)-		613
	ethylcarbamoyl]-7-fluoro-2(S)-hydroxy-
	7-methyl-octyl}-amide
233.	Quinoxaline-2-carboxylic acid {1(S)-		631,
	benzyl-4(R)-[2-(3,4-dimethoxy-phenyl)-		613
	ethylcarbamoyl]-7-fluoro-2(S)-hydroxy-
	7-methyl-octyl}-amide
234.	Quinoxaline-2-carboxylic acid {1(S)-	155.5-156.5	547
	benzyl-7-fluoro-4(R)-[(furan-2-
	ylmethyl)-carbamoyl]-2(S)-hydroxy-7-
	methyl-octyl}-amide
235.	Quinoxaline-2-carboxylic acid {1(S)-		631,
	benzyl-4(R)-[2-(2,5-dimethoxy-phenyl)-		613
	ethylcarbamoyl]-7-fluoro-2(S)-hydroxy-
	7-methyl-octyl}-amide
236.	Quinoxaline-2-carboxylic acid	114-115	587,
	[1(S)-benzyl-7-fluoro-2(S)-hydroxy-		569
	4(R)-(4-methoxy-benzylcarbamoyl)-7-
	methyl-octyl]-amide
237.	Quinoxaline-2-carboxylic acid	150-152	505,
	1(S)-benzyl-4(R)-carbamoyl-6-		487
	cyclohexyloxy-2(S)-hydroxy-hexyl)-
	amide
238.	Quinoxaline-2-carboxylic acid {4(R)-		596
	[(1H-benzoimidazol-2-ylmethyl)-
	carbamoyl]-1(S)-benzyl-7-fluoro-2(S)-
	hydroxy-7-methyl-octyl}-amide
239.	Quinoxaline-2-carboxylic acid [1(S)-	217-219	551,
	benzyl-7-fluoro-2(S)-hydroxy-4(R)-		533
	(2(S)-hydroxymethyl-pyrrolidine-1-
	carbonyl)-7-methyl-octyl]-amide
240.	Quinoxaline-2-carboxylic acid {1(S)-	111-115	551,
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-		533
	4(R)-[(tetrahydrofuran-2-ylmethyl)-
	carbamoyl]-octyl}-amide
241.	Quinoxaline-2-carboxylic acid [1(S)-	176-179	497,
	benzyl-4(S)-carbamoyl-4-(4,4-difluoro-		478
	cyclohexyl)-2(S)-hydroxy-butyl]-amide
242.	Quinoxaline-2-carboxylic acid	99-101
	[1(S)-benzyl-4(R)-(2,3-dimethoxy-
	benzylcarbamoyl)-7-fluoro-2(S)-
	hydroxy-7-methyl-octyl]-amide
243.	Quinoxaline-2-carboxylic acid [1(S)-	187-189	477,
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-		379
	(1-hydroxy-cyclohexyl)-butyl]-amide;
244.	Quinoxaline-2-carboxylic acid [1(S)-	195-198	491
	benzyl-4(S)-carbamoyl-4-(2,6-dimethyl-
	tetrahydro-pyran-4-yl)-2(S)-hydroxy-
	butyl]-amide;
245.	Quinoxaline-2-carboxylic acid	225-227	485,
	[4(R)-carbamoyl-7-fluoro-1(S)-(3-		467
	fluoro-benzyl)-2(S)-hydroxy-7-methyl-
	octyl]-amide
246.	7,8-Difluoro-quinoline-3-carboxylic acid	>220	502,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		485
	2(S)-hydroxy-7-methyl-octyl)-amide
247.	N-1(S)-Benzyl-4(R)-carbamoyl-7-	>220	484,
	fluoro-2(S)-hydroxy-7-methyl-octyl)-		466
	5,6-dichloro-nicotinamide
248.	Benzofuran-2-carboxylic acid 1(S)-	190-192	455,
	benzyl-4(R)-carbamoyl-7-fluoro-2(S)-		438
	hydroxy-7-methyl-octyl)-amide
249.	Cinnoline-4-carboxylic acid 1(S)-	198-199.5	469,
	benzyl-4(R)-carbamoyl-7-fluoro-2(S)-		451
	hydroxy-7-methyl-octyl)-amide
250.	Quinoxaline-2-carboxylic acid	185.5-187.5	593,
	[4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-		576
	1(S)-(4-iodo-benzyl)-7-methyl-octyl]-
	amide,
251.	Pyrazine-2-carboxylic acid	211-212	417,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		319
	2(S)-hydroxy-7-methyl-octyl)-amide,
252.	6,7,8-Trifluoro-quinoline-3-carboxylic	195-197	520,
	acid		503
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-
	2(S)-hydroxy-7-methyl-octyl)-amide,
253.	Quinoline-6-carboxylic acid	170-173	466,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		449
	2(S)-hydroxy-7-methyl-octyl)-amide,
254.	Isoquinoline-3-carboxylic acid	194-197	466,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		448
	2(S)-hydroxy-7-methyl-octyl)-amide,
255.	2-Methoxy-quinoline-3-carboxylic acid	213-216	496,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		479
	2(S)-hydroxy-7-methyl-octyl)-amide,
256.	1H-Benzoimidazole-2-carboxylic acid	168-169	456,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		438
	2(S)-hydroxy-7-methyl-octyl)-amide,
257.	Benzothiazole-2-carboxylic acid	152.5-155	472,
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-		455
	2(S)-hydroxy-7-methyl-octyl)-amide
258.	5-Methyl-pyrazine-2-carboxylic acid	194-197	431
	1(S)-benzyl-4(R)-carbamoyl-7-fluoro-
	2(S)-hydroxy-7-methyl-octyl)-amide
259.	Quinoxaline-2-carboxylic acid		470,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		453
	hydroxy-5-pyridin-3-yl-pentyl)-amide
260.	Quinoxaline-2-carboxylic acid [1(S)-	210-211	477,
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-		459
	(1-hydroxy-cyclohexyl)-butyl]-amide;
261.	Quinoline-3-carboxylic acid (1(S)-	231	460,
	benzyl-4(S)-carbamoyl-4-cyclohexyl-		443
	2(S)-hydroxy-butyl)-amide
262.	Quinoline-2-carboxylic acid (1(S)-	208-210	460,
	benzyl-4(S)-carbamoyl-4-cyclohexyl-		443
	2(S)-hydroxy-butyl)-amide
263.	Fluoro-quinoline-3-carboxylic acid	238-240	478,
	(1(S)-benzyl-4(S)-carbamoyl-4-		461
	cyclohexyl-2(S)-hydroxy-butyl)-amide
264.	N-(1(S)-Benzyl-4(S)-carbamoyl-4-	174-177	461
	cyclohexyl-2(S)-hydroxy-butyl)-5,6-
	dichloro-nicotinamide;
265.	N-(1(S)-Benzyl-4(S)-carbamoyl-4-	255-256	475,
	cyclohexyl-2(S)-hydroxy-butyl)-5-		458
	bromo-nicotinamide;
266.	Quinoxaline-2-carboxylic acid	159-160.5	453
	(4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-
	7-methyl-1(S)-phenyl-octyl)-amide,
267.	Quinoxaline-2-carboxylic acid		470,
	1(S)-benzyl-4(R)-carbamoyl-2(S)-		453
	hydroxy-5-pyridin-2-yl-pentyl)-amide,
268.	Quinoxaline-2-carboxylic acid [4(R)-	206-207	482
	carbamoyl-2(S)-hydroxy-4-(1-hydroxy-
	cyclohexyl)-1(S)-thiophen-2-ylmethyl-
	butyl]-amide;
269.	Quinoxaline-2-carboxylic acid [1(S)-	123-125	495,
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-		379
	(4-hydroxy-tetrahydro-thiopyran-4-yl)-
	butyl]-amide;
270.	1,3-Dimethyl-1H-pyrazolo[3,4-	189.5-191	484,
	b]pyridine-5-carboxylic acid 1(S)-		467
	benzyl-4(R)-carbamoyl-7-fluoro-2(S)-
	hydroxy-7-methyl-octyl)-amide,
271.	Quinoxaline-2-carboxylic acid (1(S)-	165-166
	benzyl-7-fluoro-2(S)-hydroxy-4(R)-
	hydroxycarbamoyl-7-methyl-octyl)-
	amide
272.	Quinoxaline-2-carboxylic acid (1(S)-
	benzyl-7-fluoro-2(S)-hydroxy-4(R)-
	methoxycarbamoyl-7-methyl-octyl)-
	amide
273.	7,8-Difluoro-quinoline-3-carboxylic acid	233-235
	(1(S)-benzyl-4(R)-carbamoyl-2(S)-
	hydroxy-5-phenyl-pentyl)-amide
274.	Quinoxaline-2-carboxylic acid [1(S)-	182-185
	benzyl-4(R)-carbamoyl-5-(2-chloro-
	phenyl)-2(S)-hydroxy-pentyl]-amide
275.	Quinoxaline-2-carboxylic acid (1(S)-	168-171
	benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-
	o-tolyl-pentyl)-amide
276.	Quinoxaline-2-carboxylic acid (1(S)-	190-192
	benzyl-2(S)-hydroxy-4(R)-
	hydroxycarbamoyl-5-phenyl-pentyl)-
	amide
277.	Quinoxaline-2-carboxylic acid [1(S)-	192-195	463,
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-		446
	(1-hydroxy-cyclopentyl)-butyl]-amide
278.	Quinoxaline-2-carboxylic acid [1(S)-	230-233	490
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(1-hydroxy-4-methyl-cyclohexyl)-butyl]-
	amide
279.	Quinoxaline-2-carboxylic acid [1(S)-	199-201
	benzyl-4(S)-carbamoyl-5-(3,4-dichloro-
	phenyl)-2(S)-hydroxy-pentyl]-amide
280.	Quinoxaline-2-carboxylic acid [1(S)-	171-173
	benzyl-4(R)-carbamoyl-5-(2-fluoro-
	phenyl)-2(S)-hydroxy-pentyl]-amide
281.	Quinoxaline-2-carboxylic acid [1(S)-	110-112	477
	benzyl-2(S)-hydroxy-4(S)-
	hydroxycarbamoyl-4-(1-hydroxy-
	cyclopentyl)-butyl]-amide
282.	Quinoxaline-2-carboxylic acid [1(S)-	187-188	476
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(1-hydroxy-3-methyl-cyclopentyl)-butyl]-
	amide
283.	Quinoxaline-2-carboxylic acid [1(S)-	114-116	506
	benzyl-2(S)-hydroxy-4(S)-
	hydroxycarbamoyl-4-(1-hydroxy-4-
	methyl-cyclohexyl)-butyl]-amide
284.	N-(1(S)-Benzyl-4(R)-carbamoyl-2(S)-		494,
	hydroxy-5-phenyl-pentyl)-5-bromo-		496
	nicotinamide
285.	8-Fluoro-quinoline-3-carboxylic acid	206-209
	(1(S)-benzyl-4(R)-carbamoyl-2(S)-
	hydroxy-5-phenyl-pentyl)-amide
286.	6,7-Dihydro-5H-[1]pyrindine-3-	182-186
	carboxylic acid (1(S)-benzyl-4(R)-
	carbamoyl-2(S)-hydroxy-5-phenyl-
	pentyl)-amide
287.	Quinoline-3-carboxylic acid (1(S)-	203-206
	benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-
	phenyl-pentyl)-amide
288.	Quinoxaline-2-carboxylic acid [1(S)-	234-236	504
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(1-hydroxy-3,5-dimethyl-cyclohexyl)-
	butyl]-amide
289.	Quinoxaline-2-carboxylic acid [1(S)-		520
	benzyl-2(S)-hydroxy-4(S)-
	hydroxycarbamoyl-4-(1-hydroxy-3,5-
	dimethyl-cyclohexyl)-butyl]-amide
290.	Quinoxaline-2-carboxylic acid [1(S)-	189-191	491
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(1-hydroxy-cycloheptyl)-butyl]-amide
291.	Quinoxaline-2-carboxylic acid [1(S)-	118-119	506
	benzyl-2(S)-hydroxy-4(S)-
	hydroxycarbamoyl-4-(1-hydroxy-
	cycloheptyl)-butyl]-amide
292.	Quinoxaline-2-carboxylic acid [1(S)-	176-179
	benzyl-4(R)-carbamoyl-5-(3-fluoro-
	phenyl)-2(S)-hydroxy-pentyl]-amide
293.	Quinoxaline-2-carboxylic acid (1(S)-	178-179
	benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-
	m-tolyl-pentyl)-amide
294.	Quinoxaline-2-carboxylic acid (1(S)-	146-148
	benzyl-2(S)-hydroxy-4-
	isobutylcarbamoyl-butyl)-amide
295.	Quinoxaline-2-carboxylic acid [1(S)-	206-207	528
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(2-hydroxy-adamantan-2-yl)-butyl]-
	amide
296.	Quinoxaline-2-carboxylic acid [1(S)-	268-269	516
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(9-hydroxy-bicyclo[3.3.1]non-9-yl)-
	butyl]-amide
297.	Quinoxaline-2-carboxylic acid [1(S)-	133-134	544
	benzyl-2(S)-hydroxy-4(S)-(2-hydroxy-
	adamantan-2-yl)-4-hydroxycarbamoyl-
	butyl]-amide
298.	Quinoxaline-2-carboxylic acid [1(S)-	130-132	532
	benzyl-2(S)-hydroxy-4(S)-(9-hydroxy-
	bicyclo[3.3.1]non-9-yl)-4-
	hydroxycarbamoyl-butyl]-amide
299.	Quinoxaline-2-carboxylic acid [1(S)-	147-148
	benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-
	(3-methoxy-phenyl)-pentyl]-amide
300.	Quinoxaline-2-carboxylic acid [1(S)-	227-228	519
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(1-hydroxy-4-propyl-cyclohexyl)-butyl]-
	amide
301.	Quinoxaline-2-carboxylic acid [1(S)-	115-117	533
	benzyl-2(S)-hydroxy-4(S)-
	hydroxycarbamoyl-4-(1-hydroxy-4-
	propyl-cyclohexyl)-butyl]-amide
302.	Quinoxaline-2-carboxylic acid [1(S)-		500,
	benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-		483
	(4-methoxy-phenyl)-pentyl]-amide
303.	Quinoxaline-2-carboxylic acid [1(S)-	246-248	504
	benzyl-4(S)-carbamoyl-4(S)-(4-ethyl-1-
	hydroxy-cyclohexyl)-2-hydroxy-butyl]-
	amide
304.	Quinoxaline-2-carboxylic acid [1(S)-	210-211	505
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(1-hydroxy-4,4-dimethyl-cyclohexyl)-
	butyl]-amide
305.	Quinoxaline-2-carboxylic acid [1(S)-	118-123	520
	benzyl-2(S)-hydroxy-4(S)-
	hydroxycarbamoyl-4-(1-hydroxy-4,4-
	dimethyl-cyclohexyl)-but yl]-amide
306.	Quinoxaline-2-carboxylic acid [1(S)-	207.5-208.5
	benzyl-4(S)-carbamoyl-4-(4,4-difluoro-
	1-hydroxy-cyclohexyl)-2(S)-hydroxy-
	butyl]-amide
307.	Quinoxaline-2-carboxylic acid [1(S)-	130-131	572
	benzyl-4(S)-(4,4-difluoro-1-hydroxy-
	cyclohexyl)-2(S)-hydroxy-4-
	hydroxycarbamoyl-but yl]-amide
308.	Quinoxaline-2-carboxylic acid [1(S)-	250-252	545
	benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-
	(1-hydroxy-4-trifluoromethyl-
	cyclohexyl)-butyl]-amide
309.	Quinoxaline-3-carboxylic acid 1(S)-	94-98	454
	cyclohexylmethyl-2(S)-hydroxy-6-
	methyl-4(R)-methylcarbamoyl-heptyl)-
	amide
310.	Quinoxaline-2-carboxylic acid [1(S)-	174-175.5	522
	benzyl-7-fluoro-2(S)-hydroxy-7-methyl-
	4(R)-(pyrrolidine-1-carbonyl)-octyl]-
	amide
311.	N-(1(S)-Benzyl-4(S)-carbamoyl-4-	218-220	470
	cyclohexyl-2(S)-hydroxy-butyl)-5-
	bromo-nicotinamide
312.	Quinoxaline-2-carboxylic acid (1(S)-	147-149	482, 467
	benzyl-7-fluoro-4(R)-
	hydrazinocarbonyl-2(S)-hydroxyl-7-
	methyl-octyl)-amide

Claims

1. A compound of the formula

2. A compound according to claim 1, wherein said compound of formula I has the exact stereochemistry depicted in formula

3. A compound according to claim 1, wherein R1 is optionally substituted pyrazolo[3,4-b]pyridinyl, cinnolinyl, pyridinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzothiazolyl, indolyl, pyrazinyl, benzoimidazolyl, benzofuranyl, benzo[b]thiophenyl, naphthalenyl, quinoxalinyl, isoquinolinyl, 5,6,7,8-tetrahydro-quinolin-3-yl or quinolinyl.

4. A compound according to claim 2, wherein R1 is optionally substituted pyrazolo[3,4-b]pyridinyl, cinnolinyl, pyridinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzothiazolyl, indolyl, pyrazinyl, benzoimidazolyl, benzofuranyl, benzo[b]thiophenyl, naphthalenyl, quinoxalinyl, isoquinolinyl, 5,6,7,8-tetrahydro-quinolin-3-yl or quinolinyl.

5. A compound according to claim 1, wherein R1 is optionally substituted pyrazolo[3,4-b]pyridin-5-yl, cinnolin-4-yl, pyridin-2-yl, 6,7-dihydro-5H-[1]pyrindin-3-yl, benzothiazol-2-yl, indol-2-yl, pyrazin-2-yl, benzoimidazol-2-yl, benzofuran-2-yl, benzo[b]thiophen-2-yl, naphthalen-2-yl, quinoxalin-2-yl, quinoxalin-6-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, 5,6,7,8-tetrahydro-quinolin-3-yl, quinolin-2-yl, quinolin-3-yl, quinolin-4-yl or quinolin-6-yl.

6. A compound according to claim 2, wherein R1 is optionally substituted pyrazolo[3,4-b]pyridin-5-yl, cinnolin-4-yl, pyridin-2-yl, 6,7-dihydro-5H-[1]pyrindin-3-yl, benzothiazol-2-yl, indol-2-yl, pyrazin-2-yl, benzoimidazol-2-yl, benzofuran-2-yl, benzo[b]thiophen-2-yl, naphthalen-2-yl, quinoxalin-2-yl, quinoxalin-6-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, 5,6,7,8-tetrahydro-quinolin-3-yl, quinolin-2-yl, quinolin-3-yl, quinolin-4-yl or quinolin-6-yl.

7. A compound according to claim 1, wherein R1 is optionally substituted quinoxalin-2-yl, quinoxalin-6-yl, quinolin-2-yl, quinolin-3-yl, quinolin-4-yl or quinolin-6-yl.

8. A compound according to claim 2, wherein R1 is optionally substituted quinoxalin-2-yl, quinoxalin-6-yl, quinolin-2-yl, quinolin-3-yl, quinolin-4-yl or quinolin-6-yl.

9. A compound according to claim 1, wherein R2 is optionally substituted benzyl.

10. A compound according to claim 2, wherein R2 is optionally substituted benzyl.

11. A compound according to claim 3, wherein R2 is optionally substituted benzyl.

12. A compound according to claim 4, wherein R2 is optionally substituted benzyl.

13. A compound according to claim 5, wherein R2 is optionally substituted benzyl.

14. A compound according to claim 6, wherein R2 is optionally substituted benzyl.

15. A compound according to claim 7, wherein R2 is optionally substituted benzyl.

16. A compound according to claim 8, wherein R2 is optionally substituted benzyl.

17. A compound according to claim 1, wherein R3 is optionally substituted (C1-C10)alkyl or (C3-C10)cycloalkyl-(CH2)n—.

18. A compound according to claim 2, wherein R3 is optionally substituted (C1-C10)alkyl or (C3-C10)cycloalkyl-(CH2)n—.

19. A compound according to claim 6, wherein R3 is optionally substituted (C1-C10)alkyl or (C3-C10)cycloalkyl-(CH2)n—.

20. A compound according to claim 8, wherein R3 is optionally substituted (C1-C10)alkyl or (C3-C10)cycloalkyl-(CH2)n—.

21. A compound according to claim 1, wherein R3 is optionally substituted n-butyl, t-butyl, isobutyl, n-pentyl, 2-methyl-pentyl, cyclopentyl, or cyclohexyl.

22. A compound according to claim 2, wherein R3 is optionally substituted n-butyl, t-butyl, isobutyl, n-pentyl, 2-methyl-pentyl, cyclopentyl, or cyclohexyl.

23. A compound according to claim 6, wherein R3 is optionally substituted n-butyl, t-butyl, isobutyl, n-pentyl, 2-methyl-pentyl, cyclopentyl, or cyclohexyl.

24. A compound according to claim 8, wherein R3 is optionally substituted n-butyl, t-butyl, isobutyl, n-pentyl, 2-methyl-pentyl, cyclopentyl, or cyclohexyl.

25. A compound according to claim 1, wherein R3 is substituted by fluoro or hydroxy.

26. A compound according to claim 2, wherein R3 is substituted by fluoro or hydroxy.

27. A compound according to claim 1, wherein R3 is 4,4-difluoro-cyclohexylmethyl, 2-fluoro-2-methyl-butyl, isobutyl, or 1-hydroxy-cyclohexyl.

28. A compound according to claim 2, wherein R3 is 4,4-difluoro-cyclohexylmethyl, 2-fluoro-2-methyl-butyl, isobutyl, or 1-hydroxy-cyclohexyl.

29. A compound according to claim 6, wherein R3 is 4,4-difluoro-cyclohexylmethyl, 2-fluoro-2-methyl-butyl, isobutyl, or 1-hydroxy-cyclohexyl.

30. A compound according to claim 8, wherein R3 is 4,4-difluoro-cyclohexylmethyl, 2-fluoro-2-methyl-butyl, isobutyl, or 1-hydroxy-cyclohexyl.

31. A compound according to claim 16, wherein R3 is 4,4-difluoro-cyclohexylmethyl, 2-fluoro-2-methyl-butyl, isobutyl, or 1-hydroxy-cyclohexyl.

32. A compound according to claim 1, wherein said compound is: 7,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide; 8-fluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-7-fluoro-1-(3(S)-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1-(2(S)-fluoro-benzyl)-2(S)-hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [I (S)-benzyl-4(S)-carbamoyl-4(S)-(2,6-dimethyl-tetrahydro-pyran-4-yl)-2(S)-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl-pentyl)-amide; quinoxaline-2-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4-(1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-(4,4-difluoro-1-hydroxy-cyclohexyl)-2(S)-hydroxy-4-hydroxycarbamoyl-but yl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-4(S)-(4,4-difluoro-cyclohexyl)-2(S)-hydroxy-butyl]-amide; quinoline-3-carboxylic acid (1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-butyl)-amide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-1(S)-thiophen-2-ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-chloro-2(S)-hydroxy-oct-6-enyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl-pentyl)-amide; N-1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-5,6-dichloro-nicotinamide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-1(S)-thiazol-4(R)-ylmethyl-octyl)-amide; benzothiazole-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide; or benzofuran-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide.

33. A pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, acute and chronic inflammatory conditions, allergic conditions, infection associated with inflammation, viral, transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.

34. A pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting MIP-1α binding to the receptor CCR1 in a mammal, comprising an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.

35. A method for treating or preventing a disorder or condition selected from autoimmune diseases, acute and chronic inflammatory conditions, allergic conditions, infection associated with inflammation, viral, transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.

36. A method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.

37. A pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, acute and chronic inflammatory conditions, allergic conditions, infection associated with inflammation, viral, transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous in a mammal, comprising a CCR1 receptor antagonizing effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

38. A pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, comprising a CCR1 receptor antagonizing effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.